

2-Oxaadamant-1-yl ureas as soluble epoxide hydrolase inhibitors: *in vivo* evaluation in a murine model of acute pancreatitis

Sandra Codony, Eugènia Pujol, Javier Pizarro-Delgado, Ferran Feixas, Elena Valverde, María Isabel Loza, José M. Brea, Elena Sáez, Julen Oyarzabal, Antonio Pineda-Lucena, Belén Pérez, Concepcion Perez, María Isabel Rodríguez-Franco, Rosana Leiva, Sílvia Osuna, Christophe Morisseau, Bruce D. Hammock, Manuel VaÁ´zquez-Carrera, and Santiago Vazquez

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.0c00310 • Publication Date (Web): 06 Aug 2020

Downloaded from pubs.acs.org on August 9, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

2-Oxaadamant-1-yl ureas as soluble epoxide hydrolase inhibitors: *in vivo* evaluation in a murine model of acute pancreatitis

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Sandra Codony¹, Eugènia Pujol¹, Javier Pizarro^{2,3,4}, Ferran Feixas⁵, Elena

Valverde^{1,2}, M. Isabel Loza⁶, José M. Brea⁶, Elena Saez⁷, Julen Oyarzabal⁷,

Antonio Pineda-Lucena⁷, Belén Pérez⁸, Concepción Pérez⁹, María Isabel

Rodríguez-Franco⁹, Rosana Leiva¹, Sílvia Osuna^{5,10}, Christophe Morisseau¹¹,

Bruce D. Hammock¹¹, Manuel Vázquez-Carrera^{2,3,4}, Santiago Vázquez^{1}*

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

¹Laboratori de Química Farmacèutica (Unitat Associada al CSIC), and

²Pharmacology, Departament de Farmacologia, Toxicologia i Química Terapèutica,

Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine

(IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.

1
2
3 ³Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases
4
5 (CIBERDEM)-Instituto de Salud Carlos III, 28029 Madrid, Spain.
6
7

8
9 ⁴Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat,
10
11 Spain.
12
13

14
15 ⁵CompBioLab Group, Departament de Química and Institut de Química
16
17 Computacional i Catàlisi (IQCC), Universitat de Girona, C/ Maria Aurèlia Capmany
18
19
20
21 69, 17003 Girona, Spain.
22
23

24
25
26 ⁶Drug Screening Platform/Biofarma Research Group, CIMUS Research Center.
27
28
29 University of Santiago de Compostela (USC), 15782 Santiago de Compostela,
30
31
32 Spain.
33
34
35

36
37
38 ⁷Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for
39
40 Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
41
42
43

44
45 ⁸Department of Pharmacology, Therapeutics and Toxicology, Institute of
46
47
48 Neurosciences, Autonomous University of Barcelona, 08193 Bellaterra, Barcelona,
49
50
51 Spain.
52
53
54
55
56
57
58
59
60

1
2
3
4 ⁹Institute of Medicinal Chemistry, Spanish National Research Council (CSIC),
5
6
7 C/Juan de la Cierva 3, 28006 Madrid, Spain.
8
9

10
11 ¹⁰Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona,
12
13
14
15 Spain.
16
17

18
19 ¹¹Department of Entomology and Nematology and Comprehensive Cancer Center,
20
21
22
23 University of California, Davis, CA 95616, USA.
24
25

26
27
28
29
30
31 KEYWORDS: acute pancreatitis, inflammation, oxaadamantane, soluble epoxide
32
33
34
35 hydrolase, urea.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

In vivo pharmacological inhibition of soluble epoxide hydrolase (sEH) reduces inflammatory diseases, including acute pancreatitis (AP). Adamantyl ureas are very potent sEH inhibitors but the lipophilicity and metabolism of the adamantane group compromises their overall usefulness. Herein, we report that the replacement of a methylene unit of the adamantane group by an oxygen atom increases the solubility, permeability and stability of three series of urea-based sEH inhibitors. Most of these oxa-analogs are nanomolar inhibitors of both the human and murine sEH. Molecular dynamics simulations rationalize the molecular basis for their activity and suggest that the presence of the oxygen atom on the adamantane scaffold results in active site rearrangements to establish a weak hydrogen bond. The 2-oxaadamantane **22**, which has a good solubility, microsomal stability and selectivity for sEH was selected for further *in vitro* and *in vivo* studies in models of cerulein-induced AP. Both in prophylactic and treatment studies, **22** diminished the overexpression of

1
2
3 inflammatory and endoplasmic reticulum stress markers induced by cerulein and
4
5
6
7 reduced the pancreatic damage.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Arachidonic acid (AA) is a polyunsaturated fatty acid that is released from membrane phospholipids of activated cells by the action of phospholipase A2 stimulation. AA can be converted into different metabolites, which can either enhance inflammation or help in its resolution. The cyclooxygenases (COXs) and the lipoxygenases (LOXs) convert AA to pro-inflammatory and nociceptive prostaglandins and leukotrienes, respectively.¹ Both pathways have been pharmaceutically targeted.² In contrast, a third metabolic route, the cytochrome P450 pathway, has been scarcely explored. Cytochrome enzymes can convert AA to the epoxyeicosatrienoic acids (EETs), which are endowed with potent anti-inflammatory properties.³⁻⁵ However, soluble epoxide hydrolase (sEH, *EPHX2*, EC 3.3.2.3) rapidly hydrolyzes EETs to their corresponding dihydroxyeicosatrienoic acids (DiHETrEs), that show altered biological activity.⁶⁻⁷ *In vivo* pharmacological inhibition of sEH has been previously shown to stabilize the concentration of EETs, reducing inflammation and pain, suggesting that sEH is a potential target for the treatment of various diseases.⁸⁻⁹

1
2
3 Structural studies revealed that sEH has an L-shaped hydrophobic pocket with the
4
5
6
7 catalytic residues at the corner.¹⁰⁻¹¹ Ureas, amides and carbamates were shown to
8
9
10 bind strongly to the catalytic residues of sEH. Taking into account the characteristics
11
12
13
14 of the active site and the overall high hydrophobicity of the pocket, the introduction
15
16
17 of lipophilic groups on both sides of the central urea has proven a successful strategy
18
19
20
21 for the space-filling of the cavity and increasing van der Waals interactions, leading
22
23
24 to several potent sEH inhibitors.¹² Indeed, a vast number of potent sEH inhibitors
25
26
27
28 incorporate an adamantane moiety, including AR9281, the first sEH inhibitor to enter
29
30
31 clinical trials (Figure 1).¹³⁻¹⁵
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Adamantane-based sEH inhibitors **1** (AR9281, APAU, UC1153), **2** (*l*-AUCB),¹⁶ and **3**.¹⁷


1
2
3 However, regardless of the efforts made to procure drug candidates with excellent
4
5
6
7 inhibitory activities, the pronounced lipophilicity of the adamantane group
8
9
10
11 compromises negatively the overall water solubility of the molecule, an important
12
13
14 physicochemical parameter in the early stages of drug discovery,¹⁸⁻¹⁹ thus limiting
15
16
17 the discovery of new drug-like sEH inhibitors.
18
19

20
21 To solve this problem, we hypothesized that the introduction of an oxygen atom
22
23
24 should increase the solubility and may impact in the overall drug-like properties of
25
26
27 the known adamantane-based sEH inhibitors without seriously compromising the
28
29
30 inhibitory potency. Taking into account the availability of several oxapolycyclic
31
32
33 amines,²⁰⁻²³ herein we have replaced the adamantane nucleus of known sEH
34
35
36
37 inhibitors by selected polycyclic scaffolds bearing an oxygen atom. Encouragingly,
38
39
40
41 previous research conducted around adamantane surrogates showed that the 2-
42
43
44 oxaadamant-1-yl substituent is a suitable replacement moiety for the clinically
45
46
47
48 approved antiviral drug amantadine.²⁴
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS AND DISCUSSION

Chemistry. To test our hypothesis, the adamantane core present in inhibitor **3** was initially replaced by three known oxapolycyclic amines, **5**, **6** and **8**.²⁰⁻²³ The reaction of commercially available 2,3,4-trifluorophenylisocyanate with **5**, **6** and **8** gave ureas **4**, **7** and **9**, respectively, in 83, 94 and 94% yield (Scheme 1).

Scheme 1. Synthesis of 2,3,4-trifluorophenyl-derived ureas, **4**, **7** and **9**.




1
2
3
4 The three ureas were tested as human sEH inhibitors using a previously reported
5
6
7 fluorescent-based assay.²⁵ The three compounds displayed IC₅₀ values in the same
8
9
10 range of potency (47.4, 21.3 and 31.3 nM, for **4**, **7**, and **9**, respectively), although
11
12
13
14 less potent than **3** (IC₅₀ = 7.7 nM).

15
16
17 Taking into account that, i) the 2-oxadamantane-1-amine **6** was synthetically much more
18
19 accessible than its isomer 2-oxadamantane-5-amine, **5**, and ii) the chiral nature of amine **8**,
20
21 the synthesis of the oxa-analogs of AR9281 and *t*-AUCB was subsequently performed only
22
23 with amine **6**.

24
25
26 For the synthesis of urea **12**, amine **6** was treated with triphosgene to yield isocyanate **10**,
27
28 which was then reacted with the commercially available 1-acetyl-4-aminopiperidine, **11**.
29
30 Similarly, the reaction of **10** with 4-((*trans*-4-aminocyclohexyl)oxy)benzoic acid, **13**,
31
32 prepared as previously reported,²⁶ furnished urea **14** (Scheme 2).

33
34
35
36
37
38
39 **Scheme 2.** Synthesis of ureas **12** and **14**.^a






1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^aReagents and conditions: a) Triphosgene, sat. NaHCO₃, DCM, 30 min; b) **11**, DCM, overnight, 52% overall yield; c) **13**, DCM, overnight, 24% overall yield. See Experimental Section and Supporting Information for further details.

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interestingly, although less potent than their hydrocarbon counterparts, the novel oxaadamantane-derived ureas were nanomolar inhibitors of the human sEH (see Table 1). Often, a high melting point is indicative for bad physical properties such as low solubility in water and organic solvents. The adamantane-derived inhibitors have limited solubility in water and high melting points (Table 1), which likely affect their *in vivo* efficacy and certainly make formulation difficult. Gratifyingly, in AR9281 and compound **3** series, the oxaadamantane derivatives exhibited lower melting points than their adamantane counterparts, while *t*-AUCB and **14** presented approximately the same value (Table 1). Remarkably, as expected, the compounds featuring the 2-oxaadamantane moiety exhibited higher solubility values, in the three series, than the ones presenting the adamantane scaffold (compare AR9281 vs **12**, *t*-AUCB vs **14**, and **3** vs **7** in Table 1). Pleasingly, in addition to the expected improvement in the solubility, the membrane permeability improved for the three series. Thus in the AR9281 (**1** and **12**) and *t*-AUCB (**2** and **14**) series, a decrease in the efflux ratio was observed when the methylene unit was replaced by an oxygen atom. On the other hand, in the trifluorophenyl analogs, the efflux ratio was already low, but the substitution led to an increase in both AB and BA permeability (see Table 1).

Table 1. Human sEH IC₅₀ and solubility, melting point and permeability values for known adamantane inhibitors AR9281, **1**, **2**, **3**, and their oxygen analogs **12**, **14** and **7**.


Compounds	X	h sEH IC ₅₀ (nM) ^[a]	Solubility (μM) ^[b]	Melting Point (°C)	Permeability (Caco-2)		ER ^[c]	
					Papp (nm/s) A→B	B→A		
	1, AR9281 (UC1153)	CH 2	8.0	24	202- 204 ^[d]	2.2	141. 2	64.5
	12	O	29.9	59	172-173	22.4	94.5	4.3
	2 , 1 AUCB	CH 2	0.5	25	250- 255 ^[e]	1.9	210. 3	111
	14	O	9.0	>100	255-257	1.4	75.5	55.4
	3	CH 2	7.7	16	216-219	6.7	4.6	0.69
	7	O	21.3	27	196-198	168	151	0.9

^aIC₅₀ values are the average of three replicates. The fluorescent assay as performed here has a standard error between 10 and 20% suggesting that differences of two-fold or greater are significant. Because of the limitations of the assay, it is difficult to distinguish among potencies < 0.5 nM.²⁵ ^bSolubility in a 1% DMSO: 99% PBS buffer solution, see Experimental Section for details. ^cThe efflux ratio was calculated as ER = (Papp B→A) / (Papp A→B). See the Experimental Section for further details. ^dTaken from reference 27. ^eTaken from reference 16.

Certainly, the introduction of the oxygen atom in the adamantane scaffold reduced the potency. Notwithstanding, designing bioactive compounds is a multifactorial process, so in

view of the significant increase in aqueous solubility and permeability and the decrease of the melting point arising from the replacement of a methylene unit of the adamantane by an oxygen atom, the synthesis of two families of analogs of **7** and **12** was undertaken using diverse right-hand side (RHS) fragments selected from previous series of known sEH inhibitors.^{15,17,28-32} After exploring their potency as sEH inhibitors, their cytotoxicity and DMPK properties were assessed for selecting a candidate to perform an *in vivo* proof of concept study in a murine model of acute pancreatitis (AP), for which a sEH inhibitor showed effectiveness at reducing symptoms.³³⁻³⁴ Of note, an *in vivo* study of the third oxa-derivative, **14**, was disclosed recently elsewhere.³⁵

Scheme 3. Synthetic procedures for the preparation of 2-oxaadmant-1-yl ureas.



Two different synthetic procedures were followed to obtain the derivatives of **7** and **12** (Schemes 3 and 4). The first route involved the synthesis of isocyanate **10** from amine **6**, followed by its reaction with the amines containing the RHS of the ureas, either directly (compounds **15** and **24-25**), or, for the less nucleophilic amines, after deprotonation with a

1
2
3 strong base such as *n*-butyllithium (compounds **26-29**). The second pathway involved the
4 reaction of amine **6** in the presence of triethylamine with the isocyanate derived from the
5 different anilines containing the RHS of the urea (compounds **30-32**).
6
7


8
9
10 The reaction of isocyanate **10** with commercially available 1-benzylpiperidin-4-amine
11 furnished urea **15**, which, upon debenylation by catalytic hydrogenation in methanol, led to
12
13
14 **16**. The reaction of piperidine **16** with commercially available 2,4-dichloro-6-methyl-1,3,5-
15 triazine furnished urea **17**, which upon reaction with methylamine led to urea **18**. Of note,
16 the triazine unit is a feature of several sEH inhibitors disclosed by GSK, including its clinical
17 candidate GSK2256294.³¹⁻³² The reaction of **16** with a series of acyl chlorides, sulfonyl
18 chlorides or carboxylic acids provided the desired ureas **19-23** in moderate to good yields.
19
20
21

22
23
24
25
26 Compound **24** was directly obtained from **10** and the commercially available 1-(4-
27 aminopiperidin-1-yl)propan-1-one. Similarly, the reaction of **10** with 1-(4-(4-
28 aminopiperidin-1-yl)phenyl)ethan-1-one, prepared as reported in the literature,³⁶ furnished
29 urea **25**. When the amines were not nucleophilic enough to attack isocyanate **10**, the presence
30 of a strong base such as *n*-butyllithium was necessary in order to deprotonate the amine. The
31 subsequent reaction of the anion with **10** led to ureas **26-29** in low to moderate yields (Scheme
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Finally, a different synthetic strategy was undertaken for the synthesis of the phenyl derivatives **30-32**, which involved the treatment of **6** with the corresponding arylisocyanates in the presence of triethylamine. In turn, the intermediate isocyanates were either commercially available or synthesized from the reaction of the corresponding anilines with triphosgene, in the presence of triethylamine in hot toluene (Scheme 4).

Scheme 4. Synthesis of new 2-oxaadamant-1-yl ureas.



^aReagents and conditions: a) Triphosgene, sat. NaHCO₃, DCM, 30 min; b) 1-benzylpiperidin-4-amine, DCM, overnight; c) H₂, Pd/C, MeOH, conc. HCl, 5 days. d) Corresponding carboxylic acid, HOBt, EDCI·HCl, Et₃N, EtOAc, 24 h; e) Corresponding sulfonyl chloride, Et₃N, DCM, overnight; f) corresponding acyl chloride, Et₃N, DCM, overnight; g) 2,4-dichloro-6-methyl-1,3,5-triazine, DIPEA, DCM, 30 min; h) Methylamine hydrochloride, DIPEA, DCM, 40 °C, 40 min; i) Corresponding amine, *n*-BuLi, anh. THF, overnight; j) Corresponding amine, DCM,


overnight; k) Triphosgene, Et₃N, toluene, 70 °C, 2 h; l) **6**·HCl, Et₃N, DCM, overnight. See Experimental Section and Supporting Information for further details.

sEH inhibition and structure-activity relationships. As a first step for the biological characterization of the novel ureas, their potency as human and murine sEH inhibitors was tested (Tables 2 and 3). In line with the good activity of **7**, compounds **30-32** were potent inhibitors of the human sEH, while the compounds featuring a heteroaromatic ring attached to the urea group, **27-29**, were poor inhibitors of the human enzyme (IC₅₀ > 500 nM). However, regardless of the presence of an aromatic or heteroaromatic ring as the RHS of the urea, all compounds were very poor inhibitors of the murine enzyme. For this reason, this set of derivatives was not further evaluated.

Table 3 collects the structures and the IC₅₀ values of ten analogs of **12**. As previously seen with the analogs of **7**, the introduction of the triazine group, **18**, yielded a poor inhibitor of the human sEH. However, the introduction of an aryl derivative, **25**, resulted into a two-digit nanomolar inhibitor. In the adamantane series of AR9281 derivatives the replacement of the methyl group of the acetyl unit in the piperidine by a broad range of alkyl and aryl substituents did not significantly impact the activity.¹⁵ By way of contrast, within our series of 2-oxadamantane derivatives, subtle variations in the *N*-substituent of the piperidine, led to significant changes. Increasing the size of the alkyl group from the methyl of **12** to propyl (**24**), cyclopropyl (**23**) and tetrahydropyranyl (**19**) resulted in a 10-15-folds reduction of the potency. Also, while the introduction of a 2-fluorophenyl group (**21**) furnished a good sEH inhibitor, the 3-pyridyl unit, as in **20**, caused a 3-folds drop in inhibitory activity. While the replacement of the acetyl group in AR9281 by a benzyl unit did not affect the inhibitory

activity,¹⁵ the same change in the 2-oxaadamantane series (**12** vs **15**) led to an important reduction (almost 40-fold) of the potency (Table 3). Finally, the substitution of the acetyl group of **12** for two alkylsulfonyl groups, as in **22** and **26**, yielded a six- and eight-fold reduction of the activity, respectively.


Table 2. Human (hsEH) and murine (msEH) sEH IC₅₀ of the aromatic and heteroaromatic series of 2-oxaadamant-1-yl ureas.




Compound	R	IC ₅₀ (nM) ^[a]	
		hsEH	msEH
7		21.3	553
27		782	14721
28		911	3853
29		1448	>100.000
30		52.6	1857
31		19.7	344
32		35.9	723

^aReported IC₅₀ values are the average of three replicates. The fluorescent assay as performed here has a standard error between 10 and 20% suggesting that differences of two-fold or greater are significant. Because of the limitations of the assay it is difficult to distinguish among potencies < 0.5 nM.²⁵

Table 3. Human (hsEH) and murine (msEH) sEH IC₅₀ of the piperidine series of 2-oxaadmant-1-yl ureas.



Compound	R	IC ₅₀ (nM) ^[a]	
		hsEH	msEH
12		29.9	92.3
15		1093	n.d. ^[b]
18		496	365
19		491	512
20		159	291
21		46	75.9

22		197	79.1
23		213	130
24		356	234
25		82.5	107
26		247	174

^aReported IC₅₀ values are the average of three replicates. The fluorescent assay as performed here has a standard error between 10 and 20% suggesting that differences of two-fold or greater are significant. Because of the limitations of the assay it is difficult to distinguish among potencies < 0.5 nM.²⁵ ^bn.d.: not determined.


Furthermore, all the compounds were also evaluated as murine sEH inhibitors (Table 3). Although there were a few minor inconsistencies, in general, the most potent compounds in the human sEH were also the most potent inhibitors of the murine sEH. Considering both the human and murine sEH inhibitory activity, compounds **12**, **21**, **22** and **25** were selected for further studies.

***In silico* study: Molecular basis of 2-oxadamant-1-yl ureas as sEH inhibitors.** To elucidate the conformational and molecular basis of the inhibitory mechanism of 2-oxadamant-1-yl ureas and, in particular, the molecular impact of the replacement of a methylene unit by an oxygen atom on the activity, Molecular Dynamics (MD) simulations of sEH were carried out in the presence of two selected compounds (**22** and **26**). The ability of sEH to recognize and properly bind both small and bulky inhibitors (as the ones depicted


1
2
3 in Tables 1-3) will depend on the grade of plasticity of its active site. Indeed, some epoxide
4 hydrolases present rich conformational dynamics of key structural elements surrounding the
5 active site, which play a crucial role for recognizing bulky epoxide substrates and inhibitors
6 of different size.³⁷ To explore the conformational dynamics of sEH, and how compounds **22**
7 and **26** are accommodated in the active site, three replicates of 250 ns of MD simulations
8 were performed for four different systems: a) in the *apo* state; b) in the presence of compound
9 **26** ($IC_{50} = 247.2$ nM) bound in the active site; c) with the inhibitor AR9273 (the hydrocarbon
10 counterpart of **26**, $IC_{50} = 1.9$ nM,¹³ PDB ID: 5ALZ³⁸) bound; and d) with compound **22** (IC_{50}
11 = 197.1 nM) present in the active site (see Figure 2). The changes on the active site volume
12 along the MD simulations were monitored using the computational tool POcket Volume
13 MEasurer (POVME)³⁹ to capture the conformational plasticity of the sEH active site. In the
14 *apo* state, the volume fluctuates between 70 and 500 Å³ providing an average value of $253 \pm$
15 62 Å³ (see Figure 2b). The high fluctuation of the active site volume in the *apo* state already
16 suggests that inhibitors of different size can fit in the binding pocket. The visual analysis of
17 the shape of the pocket clearly shows the presence of two hydrophobic pockets separated by
18 catalytic Asp335 and Tyr383 residues (L-shaped hydrophobic pocket, see Figure 2c). The
19 first hydrophobic pocket is located below the catalytic His524, which is known to
20 accommodate the adamantane moiety, according to X-ray data (see Figure 2 and PDB ID:
21 5ALZ). The other pocket is located on the right-hand site of Asp335 and Tyr383 residues
22 and encompasses also the hydrophobic entrance tunnel. The size of both pockets significantly
23 changes along the MD simulations being the “adamantane” pocket the smallest most of the
24 simulation time. When either compound **22** or **26** are bound in the active site, the average
25 volume is 361 ± 43 Å³ and 324 ± 41 Å³ respectively, in line with the bulkier isopropylsulfonyl
26 group of **22**. As shown in Figure 2b, both inhibitors restrain the flexibility of the active site
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in comparison with the significant fluctuations observed in the *apo* state. MD simulations
4 show that sEH presents a pocket with significant conformational plasticity and its breathing
5 capability can be key to recognize and bind inhibitors of different sizes.⁴⁰ Compounds **22** and
6
7
8 **26** are both capable of restricting the inner flexibility of sEH active site residues keeping the
9
10 active site blocked. The large active site volumes sampled indicate that there is room for
11
12 further functionalization of both the oxadamantyl moiety and the RHS of the urea.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4 **a) sEH X-ray structure (PDB ID: 5ALZ) in complex with AR 9723 and**
5 **catalytic residues**



24 **b) Active Site Volume Fluctuations: apo, compound 22, and compound 26**



38 **c) Representative Active Site Volumes for apo, compound 22 and compound 26**



1
2
3 **Figure 2.** a) Representation of sEH structure (PDB: 5ALZ), active site catalytic
4 residues (nucleophilic Asp335, Tyr383, Tyr466, and the histidine-aspartic acid pair
5
6
7 His524-Asp496. b) Plot of the fluctuations of the active site volume for the *apo* state
8
9
10
11 (orange line, $253 \pm 62 \text{ \AA}^3$), compound **22** bound (purple line, $361 \pm 43 \text{ \AA}^3$), and
12
13
14 compound **26** bound (red line, $324 \pm 41 \text{ \AA}^3$) along a representative 250 ns MD
15
16
17 simulation trajectory. c) Representative sEH structures with the active site volume
18
19
20
21 obtained from MD simulations of *apo*, **22**, and **26**.
22
23
24
25
26
27
28
29
30

31 To gain a deeper insight into the molecular basis of the inhibitory mechanism of 2-
32 oxaadamantyl derivatives, we monitored key interactions between the three inhibitors
33 (AR9273, **26**, and **22**) and relevant active site residues along the 250 ns MD simulations of
34 sEH (see Figure 3). The three selected distances correspond to the one between the carboxylic
35 group of the catalytic Asp335 and one of the NH groups of the inhibitor, and the distances
36 between the carbonyl group of the urea inhibitors and the OH group of either Tyr383 or
37 Tyr466 residues (Figure 3a). MD simulations show that the three hydrogen bonds remain
38 significantly stable along the whole simulation time for the hydrocarbon based AR9273
39 ($d(C_{\gamma\text{Asp335}}\text{-NH}_{\text{AR 9273}}) = 2.55 \pm 0.17 \text{ \AA}$, $d(\text{OH}_{\text{Tyr383}}\text{-O}_{\text{AR 9273}}) = 1.76 \pm 0.17 \text{ \AA}$, and $d(\text{OH}_{\text{Tyr466}}\text{-}$
40 $\text{O}_{\text{AR 9273}}) = 2.21 \pm 0.83 \text{ \AA}$). In the case of oxadamantane-based **22** and **26** compounds, the
41 hydrogen bonds are less stable than for AR9273 and fluctuate along the simulation time
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 indicating a lower affinity towards the active site of sEH ($d(C\gamma_{\text{Asp335}}\text{-NH}_{26}) = 2.66 \pm 0.19 \text{ \AA}$,
4
5 $d(\text{OH}_{\text{Tyr383}}\text{-O}_{26}) = 2.01 \pm 0.83 \text{ \AA}$, $d(\text{OH}_{\text{Tyr466}}\text{-O}_{26}) = 2.67 \pm 0.81 \text{ \AA}$ for **26** and $d(C\gamma_{\text{Asp335}}\text{-}$
6
7 $\text{NH}_{22}) = 2.74 \pm 0.40 \text{ \AA}$, $d(\text{OH}_{\text{Tyr383}}\text{-O}_{22}) = 2.50 \pm 1.54 \text{ \AA}$, $d(\text{OH}_{\text{Tyr466}}\text{-O}_{22}) = 2.06 \pm 0.71 \text{ \AA}$ for
8
9 **22**).



10
11
12
13 The simulations indicate that the adamantane group of AR9273 freely rotates inside the
14
15 hydrophobic pocket establishing weak interactions with the surrounding Tyr383, Leu408,
16
17 Met419, Val498, His524, and Trp525. This situation totally changes with the introduction of
18
19 an oxygen atom into the adamantane scaffold, which restricts the rotation of the adamantane
20
21 moiety inside the hydrophobic pocket introducing an entropic penalty that is partially
22
23 compensated by more persistent interactions with surrounding residues (see the detailed
24
25 analysis of non-covalent interactions in Figure S1). This restricted flexibility induces a dipole
26
27 moment in the pocket that reshapes the interactions between catalytic residues (see Figure
28
29 3b). Interestingly, the oxaadamantane group rapidly orients to establish an interaction
30
31 between the oxa group and both a water molecule and the positively charged His524 residue
32
33 (see Figure 3b and Figure S1). The orientation towards the water molecule occupying the
34
35 active site occurs in both **22** and **26** simulations. To unravel in more detail the network of
36
37 interactions established when the oxygen group is present in the adamantane scaffold, we
38
39 represented the non-covalent interactions (NCI) between compound **22** and active site
40
41 residues computed with NCIPLOT (see Figure S1).⁴¹ The NCI analysis reveals a hydrogen bond
42
43 interaction between the water molecule and the oxa group, and a wide ion dipole interaction
44
45 surface between the oxygen and the protonated His524. Additionally, several hydrophobic
46
47 interactions between the adamantane group and residues Phe267, Tyr383, Leu408, Leu417,
48
49 Met419, and Trp525 are observed (see Figure S1). However, in the presence of AR9273, the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 water molecule establishes a network of hydrogen bonds with His524 and Glu269 that keeps
4
5 Asp335 interacting with the NH groups of the inhibitor. In **22** and **26**, this water molecule
6
7 preferentially interacts with the oxaadamantane moiety rather than with His524, which
8
9 establishes a hydrogen bond with Asp335 that has undergone a reorientation of its side chain
10
11 (see active site rearrangements in Figure 3b). This destabilizes the interactions between
12
13 Asp335 and the carbonyl group of the inhibitor, lowering the affinity of **22** and **26** for the
14
15 sEH active site. To estimate the binding affinities, we computed the relative binding free
16
17 energy using the thermodynamic integration (TI) method between compound **22** and its
18
19 adamantane counterpart containing a methylene unit instead of an oxygen (**22-CH₂**). Both
20
21 ligands present a similar affinity towards sEH active site being the relative binding free
22
23 energy of compound **22-CH₂** with respect to compound **22** around -0.8 kcal/mol. These
24
25 observations are in line with the obtained IC₅₀ values that indicate slightly higher affinity for
26
27 adamantane derivatives. Therefore, the introduction of an oxygen atom into the adamantane
28
29 scaffold introduces a network of interactions that altogether restrict its orientation within the
30
31 hydrophobic pocket having an impact on the affinity of oxaadamantane inhibitors for sEH.
32
33
34
35
36
37



38 Finally, we assessed the *in silico* lipophilicity of compounds **22** and **22-CH₂** by computing
39
40 the LogP from the solvation free energy differences using the M06-2X functional with SMD
41
42 implicit solvation and the def2-SVP basis set.⁴² The computed LogP of compound **22** is 0.77
43
44 while the **22-CH₂** is 2.44. In line with the above reported experimental solubilities, these
45
46 results predict a significant decrease in lipophilicity when the oxygen atom is introduced in
47
48 the adamantane scaffold of compound **22**.
49
50
51
52
53
54
55
56
57
58
59
60

a) Binding Pose and Key Distances along MD simulations



AR 9273



Compound 26




Compound 22




b) Molecular Interactions Compound 22



Active Site Rearrangement 1




Active Site Rearrangement 2



Compound 22



Hydrophobic Pocket 1



Hydrophobic Pocket 2

1
2
3 **Figure 3.** a) Representative structures of AR9273, **22**, and **26** bound in the active
4
5
6
7 site of sEH obtained from MD simulations. Plot of the distance between the
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


carboxylic group of the catalytic Asp335 and the amide groups of the inhibitor (purple
line, $d_1(\text{C}_{\text{YAsp335}}\text{-NH}_{\text{INH}})$), and the distances between the carbonyl group of the urea
inhibitors and the OH group of either Tyr383 (red line, $d_2(\text{OH}_{\text{Tyr383}}\text{-O}_{\text{INH}})$) or Tyr466
residues (orange line, $d_3(\text{OH}_{\text{Tyr466}}\text{-O}_{\text{INH}})$) along the MD simulations of AR 9273
($d_1(\text{C}_{\text{YAsp335}}\text{-NH}_{\text{AR 9273}}) = 2.55 \pm 0.17 \text{ \AA}$, $d_2(\text{OH}_{\text{Tyr383}}\text{-O}_{\text{AR 9273}}) = 1.76 \pm 0.17 \text{ \AA}$, and
 $d_3(\text{OH}_{\text{Tyr466}}\text{-O}_{\text{AR 9273}}) = 2.21 \pm 0.83 \text{ \AA}$), **22** ($d_1(\text{C}_{\text{YAsp335}}\text{-NH}_{\text{22}}) = 2.66 \pm 0.19 \text{ \AA}$,
 $d_2(\text{OH}_{\text{Tyr383}}\text{-O}_{\text{22}}) = 2.01 \pm 0.83 \text{ \AA}$, $d_3(\text{OH}_{\text{Tyr466}}\text{-O}_{\text{22}}) = 2.67 \pm 0.81 \text{ \AA}$), and **26**
($d_1(\text{C}_{\text{YAsp335}}\text{-NH}_{\text{26}}) = 2.74 \pm 0.40 \text{ \AA}$, $d_2(\text{OH}_{\text{Tyr383}}\text{-O}_{\text{26}}) = 2.50 \pm 1.54 \text{ \AA}$, $d_3(\text{OH}_{\text{Tyr466}}\text{-O}_{\text{26}})$
 $= 2.06 \pm 0.71 \text{ \AA}$). b) Key molecular interactions between **22** and active site residues.

Biological profiling of the selected sEH inhibitors. The four more potent inhibitors were
characterized in terms of cytotoxicity in 2 different cell lines [Transformed Human Liver
Epithelial-2 cell line (THLE-2) and Peripheral Blood Mononuclear Cells (PBMC)],
solubility, microsomal stability (human, mouse and rat species), hERG (human ether-a-go-
go-related gene) inhibition, cytochromes P450 (CYP) inhibition and predicted brain


permeability, in order to select the best candidate to perform an *in vivo* study in a murine model of AP. None of the tested compounds showed to be cytotoxic for the THLE-2 at the highest concentration tested (100 μM). Additionally, compounds **12**, **21** and **22** were not cytotoxic in the PBMC at the highest concentration tested (20 μM) (Table 4).

Taking into account that AP is a peripherally restricted inflammatory disease, we wanted to prioritize compounds showing negative BBB permeation in order to avoid potential side effects resulting from central inhibition of sEH. The selected compounds were further tested for predicted brain permeation in the widely used *in vitro* parallel artificial membrane permeability assay-blood brain barrier (PAMPA-BBB) model.⁴³ With the sole exception of **25**, all the compounds have predicted limited BBB penetration (Table 4).

Table 4. Cytotoxicity (in THLE-2 and PBMC cell lines), PAMPA-BBB, solubility and microsomal stability values of selected compounds.



Compound	R	Cytotoxicity LC ₅₀ (μM)		PAMPA- BBB	Solubility ^[a] (μM)	Microsomal stability ^[b]		
		PBMC	THLE-2			Human	Mouse	Rat
12		>20	>100	CNS-	59	88.8	80.5	85.1
21		>20	>100	CNS-	>100	30.2	39.5	19.3

22		>20	>100	CNS-	34	72.7	63.9	63.9
25		ND	>100	CNS+	81.5	40	73	84

^aSolubility in a 1% DMSO : 99% PBS buffer solution. ^bPercentage of remaining compound after 60 min of incubation with human, mice and rat microsomes in the presence of NADPH at 37 °C. Metabolism of testosterone was used as a positive control. See Experimental Section for details.

Next, the solubility was experimentally determined in a 1% DMSO: 99% PBS buffer solution. In the adamantane series, when the methyl group of the amide of AR9281 was replaced by bigger substituents, the potency was retained or even increased, but the solubility dramatically dropped.¹⁵ Pleasantly, all the oxaadamantanes presented good to excellent solubilities (see Table 4), greater than that of the adamantane-based inhibitors **1-3**, as expected.

The microsomal stability of **12**, **21**, **22** and **25** was evaluated in human, mice and rat liver microsomes, which are widely used to determine the likely degree of primary metabolic clearance in the liver. Although compound **21** displayed unsatisfactory stabilities in the three species, and **25** presented poor stability in human microsomes, compounds **12** and **22** showed good microsomal stabilities in the three species (see Table 4). Furthermore, the study of cytochromes P450 (CYP) inhibition was performed in order to examine the inhibitory potency of **12** and **22**, the compounds with better overall microsomal stabilities, against human recombinant cytochrome P450 enzymes, mainly CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3AE, through a fluorescence-detection method. These assays were of great interest, not only for the detection of possible drug-drug interactions, but also in terms of

1
2
3 selectivity, as EETs are formed by cytochrome P450 isoforms, especially CYP2C19,
4 followed by CYP1A2 and CYP2J2 to a lesser extent. Satisfactorily, the tested compounds
5 showed very low potency (higher than 10 μM) inhibiting the different cytochromes tested
6 (see Table S2 in the Supporting Information). This potency is much lower (more than 100-
7 fold) than the potency observed either in human or murine sEH. Inhibition of the hERG
8 channel is an important toxicology screen due to its known association with cardiotoxicity.
9
10 Inhibitors **12** and **22** showed minimal inhibition on hERG at 10 μM (see Table S2 in
11 Supporting Information). Therefore, the selected inhibitors are considered not to present a
12 risk with CYP or hERG inhibition. Finally, three representative inhibitors were tested for
13 selectivity against *h*COX-2 and *h*LOX-5, two enzymes involved in the AA cascade. Neither
14 the *N*-acyl piperidines **21** and **24** nor the *N*-sulfonyl piperidine **22** displayed significant
15 inhibition of these enzymes (see Table S3 in Supporting Information).
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30
31 ***In vitro* proof of concept: Acute Pancreatitis.** AP is a serious and life-threatening
32 inflammatory disease, and one of the most common gastrointestinal disorders worldwide
33 without specific therapies available.⁴⁴⁻⁴⁶ Recently, it was shown that the EPHX2 whole-body
34 knockout (KO) mice exhibit attenuated cerulein- and arginine-induced AP,³³ and that
35 pharmacological inhibition of sEH can modulate the severity of AP before and after induction
36 of disease, due to the potent anti-inflammatory properties of the EETs and the reduction of
37 the endoplasmic reticulum (ER) stress.³⁴
38
39
40
41
42
43
44
45
46

47 In order to select a candidate for *in vivo* studies and verify the positive effect of the new sEH
48 inhibitors on AP, we performed an *in vitro* proof of concept in the AR42J pancreatic acinar
49 rat cell line that expresses sEH,⁴⁷ a well-established model for evaluating the potential
50 therapeutic activity of compounds for AP.⁴⁸⁻⁴⁹ Given that this is a rat-derived cell line and
51 the inhibitory activity of **12** and **22** was previously evaluated for the human and murine
52
53
54
55
56
57
58
59
60

enzymes (see above), we first confirmed that the selected inhibitors presented potency in the rat enzyme. Both compounds inhibited the rat sEH, being compound **22** slightly more potent than **12** (IC₅₀ of 1.9 nM and 3.3 nM, respectively).

For the *in vitro* study of efficacy, AR42J cells were treated with cerulein (Cer), a well-known inducer of AP, and with the selected compounds, following an established procedure.⁴⁹ Inflammatory (IL-6 and TNF- α) and ER stress (CHOP and TRB3) markers were measured (Figure 4). As expected, cells treated with cerulein (10 nM) showed an increase in the expression of inflammatory and ER stress markers, while co-incubation of the cells with cerulein and the sEH inhibitors **12** and **22** (60 μ M) caused a significant reduction in the mRNA levels of these markers. Notably, compound **22** completely abolished the increase in the expression of IL-6, CHOP and TRB3, and strongly attenuated the increment in TNF- α caused by cerulein exposure. Consequently, compound **22** was chosen for the *in vivo* efficacy studies in two mice models of AP. Overall, **22** has low nanomolar inhibition of the murine sEH, does not exhibit cytotoxicity, does not inhibit cytochrome P450s nor hERG, has good microsomal stability, predicted poor brain penetration and has a reasonable solubility value.




Figure 4: Results of the *in vitro* study of cerulein-induced AP in AR42J

pancreatic rat cells. *IL-6*, *TNF α* , *CHOP* and *TRB3* mRNA levels are

presented as the mean \pm SEM (n = 5 per group). **p<0.01, ***p<0.001 vs.

control. #p<0.05, ##p<0.01 vs. Cer.

Pharmacokinetic study of 22. To determine its pharmacokinetic profile in mouse, compound **22** was administered either by intravenous (iv) or intraperitoneal (ip) routes at a single dose of 1 mg/kg (see Figure S2 and Tables S4 and S5 in the supporting information). Pharmacokinetic parameters are shown in Table 5. For both administration routes, T_{max} and C_{max} values were similar. Good exposures of compound **22** were obtained, indicating bioavailability of 59%. High volumes of distribution and clearance were obtained with both administration routes, indicating that while **22** is well distributed across all tissues it is eliminated quite fast. Considering the results obtained, **22** was administered ip in the subsequent *in vivo* studies.

Table 5: Pharmacokinetic parameters in mouse for ip and iv administration routes of compound **22** at 1 mg/kg.

Route	$T_{1/2}$ (h)	T_{max} (h)	C_{max} (ng/mL)	C_0 (ng/mL)	AUC _{last} (h·ng/mL)	AUC _{INF_obs} (h·ng/mL)	V_z (L/kg)	Cl (L/h/kg)
IP	3.02	0.16	117.33	-	34.67	35.20	124.02	28.41
IV	2.80	0.16	108.33	236.23	59.1	59.63	67.73	16.77

1
2
3
4
5
6
7 **Maximum Tolerated Dose (MTD) study of 22.** In order to determine potential acute
8 toxicological effect, compound **22** was intraperitoneally daily administered to mice at
9 variable doses (5, 10, 20 and 80 mg/kg) for five consecutive days. No toxic effects were
10 observed based on body weight along the treatment, as well as the absence of apparent
11 behavior problems and petechiae, indicating that compound **22** is well tolerated.
12
13
14
15
16
17

18 ***In vivo* efficacy study.** To determine the effects of the administration of compound **22** on
19 AP, C57BL/6J mice were treated with this sEH inhibitor before (prevention) and after
20 (treatment) the induction of AP by cerulein, following already published protocols (see
21 Figure S3 in the Supporting Information and the Experimental Section).³⁴ The post-induction
22 efficacy study was performed in order to simulate a treatment study. In this protocol, cerulein
23 was administered several times before the administration of compound **22**.
24
25
26
27
28
29
30
31

32 Results of the post-induction efficacy study are shown in Figure 5. In line with previous
33 reports,³⁴ mice treated with cerulein presented a significant increase in the mRNA abundance
34 of inflammatory (TNF- α , IL-1 β and MCP-1) and ER stress (ATF3) markers. Albeit the
35 administration of compound **22** at 3 mg/kg did not cause a significant reduction of
36 inflammatory and ER stress markers, administration of 30 mg/kg produced a significant
37 reduction in the four markers studied compared to mice treated only with cerulein.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5: Results of the *in vivo* studies of cerulein-induced AP in the post- and pre-induction models. *TNF α* , *IL-1 β* , *MCP-1* and *ATF3* mRNA levels are presented as the mean \pm SEM (n = 5 per group). *p<0.05, **p<0.01, ***p<0.001 vs. control. +p<0.05, ++p<0.01 vs. cerulein (CER).

Considering that the dosage of 30 mg/kg was the one that presented significant effects on the post-induction model, the pre-induction efficacy study was performed only at 30 mg/kg. Results (Figure 5) indicate that administration of **22** significantly reduced an increase of inflammatory (TNF- α , IL1- β and MCP-1) and ER stress (ATF3) markers produced by cerulein administration. Interestingly, AP is the most common complication of the endoscopic retrograde cholangiopancreatography (ERCP), a well-established technique for

1
2
3 the treatment of pathological conditions of the biliary tract and pancreas. ERCP-related AP
4 occurs in up to 9% of ERCPs in unselected prospective studies. The severity of post-ERCP
5 pancreatitis can range from mild disease with full recovery to critical illness with necrotizing
6 pancreatitis, multiorgan failure, prolonged hospitalization, and even death.⁵⁰ The efficacy of
7 pre-induction compound **22** on AP suggests that such treatment might be of interest to
8 patients before the ERCP procedure, in order to diminish the probabilities of suffering of AP
9 as a complications of this classic procedure.
10
11
12
13
14
15
16
17
18

19 **Histopathology.** Additionally, the severity of cerulein-induced pancreatitis in control and
20 sEH inhibitor-treated mice was determined by histologic analyses. Pathologic changes were
21 studied on H&E-stained pancreas sections from control, cerulein-treated and cerulein- and
22 **22**-treated mice in both the pre-induction and post-induction AP models. As anticipated, the
23 administration of cerulein caused a significant increase in edema and inflammation. In
24 contrast, mice treated with compound **22** after or before the induction of AP exhibited a
25 significant decrease in cerulein-induced edema and inflammation (Figure 6).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6. Representative H&E-stained sections of the pancreas from the pre-induction (left) and post-induction (right) efficacy studies. CER: cerulein. Arrows indicate the presence of inflammatory cells and asterisks the presence of edema.

CONCLUSIONS

Several sEH inhibitors feature an adamantane moiety in their structure, however, its lipophilicity negatively compromises the solubility and PK properties of these compounds. In this work, a new family of sEH inhibitors bearing a 2-oxadamantane moiety in order to improve those characteristics were synthesized. Most of the compounds were nanomolar inhibitors of the human and murine sEH, although somehow less potent than their adamantane counterparts. Molecular modeling suggests that the introduction of the oxygen atom into the adamantane scaffold restricts its orientation within the hydrophobic pocket and weakens hydrogen bonds between the inhibitor and the enzyme. Biological profiling (solubility, cytotoxicity, metabolic stability, predicted BBB penetration, CYP450s and hERG

1
2
3 inhibition) allowed us to select compound **22** for *in vivo* studies in a murine model of
4
5 cerulein-induced AP. In both pre-induction and post-induction studies, **22** diminished the
6
7 overexpression of inflammatory and ER stress markers induced by cerulein and reduced
8
9 pancreatic damage. Due to the promising biological activity of **22**, further optimization of
10
11 new sEH inhibitors for the treatment of AP, an unmet medical need, is underway.
12
13

14 Finally, the adamantane unit is a typically used polycyclic scaffold in many drug discovery
15
16 programs.⁵¹⁻⁵² It is already present in nine clinically approved drugs and in many clinical
17
18 candidates. Nonetheless, the use of its oxapolycyclic analogs has largely been neglected in
19
20 drug discovery. This work may pave the way for the evaluation of less lipophilic scaffolds in
21
22 several other targets, currently being explored with adamantanes.
23
24

25 26 **EXPERIMENTAL SECTION**

27
28 **Chemical Synthesis. General methods.** Commercially available reagents and solvents were
29
30 used without further purification unless stated otherwise. Preparative normal phase
31
32 chromatography was performed on a CombiFlash Rf 150 (Teledyne Isco) with pre-packed
33
34 RediSep Rf silica gel cartridges. Thin-layer chromatography was performed with aluminum-
35
36 backed sheets with silica gel 60 F254 (Merck, ref 1.05554), and spots were visualized with
37
38 UV light and 1% aqueous solution of KMnO₄. Melting points were determined in open
39
40 capillary tubes with a MFB 595010M Gallenkamp. 400 MHz ¹H and 100.6 MHz ¹³C NMR
41
42 spectra were recorded on a Varian Mercury 400 or on a Bruker 400 Avance III spectrometers.
43
44 500 MHz ¹H NMR spectra were recorded on a Varian Inova 500 spectrometer. The chemical
45
46 shifts are reported in ppm (δ scale) relative to internal tetramethylsilane, and coupling
47
48 constants are reported in Hertz (Hz). Assignments given for the NMR spectra of selected new
49
50 compounds have been carried out on the basis of DEPT, COSY ¹H/¹H (standard procedures),
51
52 and COSY ¹H/¹³C (gHSQC and gHMBC sequences) experiments. IR spectra were run on
53
54
55
56
57

1
2
3 Perkin-Elmer Spectrum RX I, Perkin-Elmer Spectrum TWO or Nicolet Avatar 320 FT-IR
4 spectrophotometers. Absorption values are expressed as wave-numbers (cm^{-1}); only
5 significant absorption bands are given. High-resolution mass spectrometry (HRMS) analyses
6 were performed with an LC/MSD TOF Agilent Technologies spectrometer. The elemental
7 analyses were carried out in a Flash 1112 series Thermofinnigan elemental microanalyzer
8 (A5) to determine C, H, N and S. The structure of all new compounds was confirmed by
9 elemental analysis and/or accurate mass measurement, IR, ^1H NMR and ^{13}C NMR. The
10 analytical samples of all the new compounds, which were subjected to pharmacological
11 evaluation, possessed purity $\geq 95\%$ as evidenced by their elemental analyses or their
12 HPLC/MS. HPLC/MS were determined with a HPLC Agilent 1260 Infinity II LC/MSD
13 coupled to a photodiode array and mass spectrometer. 5 μL of sample 0.5 mg/mL in
14 methanol:acetonitrile were injected, using a Agilent Poroshell 120 EC-C18, 2.7 μm , 50 mm
15 x 4.6 mm column at 40 $^\circ\text{C}$. The mobile phase was a mixture of A = water with 0.05% formic
16 acid and B = acetonitrile with 0.05% formic acid, with the method described as follows: flow
17 0.6 mL/min, 5%B-95%A 3 min, 100%B 4 min, 95%B-5%A 1 min. Purity is given as % of
18 absorbance at 210 or 254 nm.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 **1-(2-oxadamant-5-yl)-3-(2,3,4-trifluorophenyl)urea, 4.** In a round-bottom flask equipped
42 with a stir bar under nitrogen atmosphere 1.2 equiv. of the 2-oxadamantyl-1-amine
43 hydrochloride was added to anh. DCM (~110 mM). To this suspension 1.0 equiv. of 2,3,4-
44 trifluorophenylisocyanate followed by 7 equiv. of triethylamine was added. The reaction
45 mixture was stirred at room temperature overnight. Then, the solvent was removed under
46 vacuum and the resulting crude was purified by column chromatography (SiO_2 ,
47 hexane/EtOAc mixtures). Evaporation under vacuum of the appropriate fractions gave urea
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **4** (24 mg, 83% yield) as a white solid. Mp 211-213 °C. IR (ATR) ν : 3344, 2937, 2856, 2478,
4
5 2362, 1681, 1621, 1556, 1504, 1473, 1434, 1402, 1361, 1320, 1288, 1236, 1183, 1146, 1107,
6
7 1076, 1035, 1020, 1005, 992, 948, 921, 890, 810, 793, 775, 761, 724, 686, 656, 636 cm^{-1} .
8
9 $^1\text{H-NMR}$ (400 MHz, CD_3OD) δ : 1.66 [dm, $J = 12.8$ Hz, 2 H, 8(10)- H_a], 1.98 [dm, $J = 12.4$
10
11 Hz, 2 H, 8(10)- H_b], 2.06 [d, $J = 12$ Hz, 2 H, 4(9)- H_a], 2.14-2.21 [complex signal, 4 H, 4(9)-
12
13 H_a , 6- H_2], 2.25 (m, 1 H, 7-H), 4.17 [broad s, 2 H, 1(3)-H], 7.01 (m, 1 H, 5'-H), 7.68 (m, 1 H,
14
15 6'-H). $^{13}\text{C-NMR}$ (100.6 MHz, CD_3OD) δ : 28.8 (CH, C7), 36.0 [CH_2 , C8(10)], 41.2 [CH_2 ,
16
17 C6], 41.8 [CH_2 , C4(9)], 50.6 (C, C5), 70.9 [CH, C1(3)], 112.2 (CH, dd, $^2J_{\text{C-F}} = 17.8$ Hz, $^3J_{\text{C-}}$
18
19 $\text{F} = 3.7$ Hz, C5'), 116.8 (CH, C6'), 126.8 (C, d, $^2J_{\text{C-F}} = 6.5$ Hz, Ar-C1'), 141.0 (C, d, $^1J_{\text{C-F}} =$
20
21 247 Hz, Ar-C3'), 143.5 (C, d, $^1J_{\text{C-F}} \sim 245$ Hz, Ar-C4'), 147.5 (C, d, $^1J_{\text{C-F}} = 242$ Hz, Ar-C2'),
22
23 156.2 (C, CO). MS (DIP), m/z (%); significant ions: 173 [$(\text{C}_7\text{H}_2\text{F}_3\text{NO})^+$, 4], 149 (100), 148
24
25 (62), 147 (16), 137 [$(\text{C}_9\text{H}_{13}\text{O})^+$, 8], 93 (49). HRMS: Calculated for $[\text{C}_{16}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2\text{-H}]^-$:
26
27 325.1169. Found: 325.1173.
28
29
30
31
32
33

34 **1-(2-oxadamant-1-yl)-3-(2,3,4-trifluorophenyl)urea, 7**. In a round-bottom flask equipped
35
36 with a stir bar under nitrogen atmosphere 1.2 equiv. of the 2-oxadamantyl-1-amine
37
38 hydrochloride was added to anh. DCM (~110 mM). To this suspension 1.0 equiv. of 2,3,4-
39
40 trifluorophenylisocyanate followed by 7 equiv. of triethylamine was added. The reaction
41
42 mixture was stirred at room temperature overnight. Then the solvent was removed under
43
44 vacuum. Purification by column chromatography (SiO_2 , hexane/EtOAc mixtures) of the
45
46 crude and evaporation under vacuum of the appropriate fractions gave urea **7** (163 mg, 94%
47
48 yield) as a white solid. Mp 196-198 °C. IR (ATR) ν : 3300-2800 (3293, 3232, 3127, 2933,
49
50 2857), 1702, 1640, 1621, 1563, 1509, 1489, 1471, 1446, 1373, 1349, 1340, 1317, 1294, 1257,
51
52 1239, 1227, 1200, 1165, 1117, 1099, 1080, 1020, 996, 976, 963, 932, 912, 884, 840, 805,
53
54
55
56
57
58
59
60

1
2
3 788, 757, 683, 653 cm⁻¹. ¹H-NMR (500 MHz, CD₃OD) δ: 1.68 [dm, *J* = 12.5 Hz, 2 H, 4(10)-
4 H_a], 1.89 [complex signal, 4 H, 6-H₂, 8(9)-H_a], 2.00 [dm, *J* = 12.5 Hz, 2 H, 4(10)-H_b], 2.26
5 [broad signal, 2 H, 5(7)-H], 2.32 [d, *J* = 12.5 Hz, 8(9)-H_b], 4.23 (broad s, 1 H, 3-H), 7.03 (m,
6 1 H, 5'-H), 7.75 (m, 1 H, 6'-H). ¹³C-NMR (125.7 MHz, CD₃OD) δ: 29.6 [CH, C5(7)], 35.6
7 [CH₂, C4(10)], 35.8 (CH₂, C6), 40.9 [CH₂, C8(9)], 72.5 (CH, C3), 82.2 (C, C1), 112.3 (CH,
8 dd, ²*J*_{C-F} = 18 Hz, ³*J*_{C-F} = 4 Hz, C5'), 116.8 (CH, C6'), 126.5 (C, d, ²*J*_{C-F} = 8.8 Hz, Ar-C1'),
9 141.0 (C, dt, ¹*J*_{C-F} = 246 Hz, ²*J*_{C-F} = 15 Hz, Ar-C3'), 143.8 (C, dd, ¹*J*_{C-F} = 244 Hz, ²*J*_{C-F} = 11
10 Hz, Ar-C4'), 147.6 (C, dd, ¹*J*_{C-F} = 244 Hz, ²*J*_{C-F} = 9 Hz, Ar-C2'), 156.0 (C, CO). HRMS:
11 Calculated for [C₁₆H₁₇F₃N₂O₂+H]⁺: 327.1315. Found: 327.1319.
12
13
14
15
16
17
18
19
20
21
22
23

24 **1-(4-oxahexacyclo[5.4.1.0^{2,6}.0^{3,10}.0^{5,9}.0^{8,11}]dodecan-3-yl)-3-(2,3,4-trifluorophenyl)urea, 9.**

25
26 In a round-bottom flask equipped with a stir bar under nitrogen atmosphere 1.2 equiv. of the
27 2-oxadamantyl-1-amine hydrochloride was added to anh. DCM (~110 mM). To this
28 suspension 1.0 equiv. of 2,4-trifluorophenyl isocyanate followed by 7 equiv. of triethylamine
29 was added. The reaction mixture was stirred at room temperature overnight. Then the solvent
30 was removed under vacuum. Purification by column chromatography (SiO₂, hexane/EtOAc
31 mixtures) of the crude and evaporation under vacuum of the appropriate fractions gave urea
32 **9** (374 mg, 94% yield) as a white solid. Mp 152-154 °C. IR (ATR) ν: 3329, 3192, 3118, 2975,
33 1701, 1641, 1621, 1559, 1509, 1470, 1342, 1321, 1287, 1253, 1205, 1183, 1166, 1127, 1071,
34 1020, 996, 951, 933, 911, 867, 839, 798, 757, 708, 688, 655, 635, 593 cm⁻¹. ¹H-NMR (400
35 MHz, CDCl₃) δ: 1.60 (dt, *J* = 10.8 Hz, *J*' = 1.6 Hz, 1 H, 12-H_a), 1.95 (dt, *J* = 10.8 Hz, *J*' =
36 1.6 Hz, 1 H, 12-H_b), 2.50 (broad t, *J* = 5.2 Hz, 1 H, 7-H), 2.57 (t, *J* = 4.8 Hz, 1 H, 1-H), 2.66
37 (m, 8 H, 2-H), 2.75-2.84 (complex signal, 3 H, 2-H, 10-H, 11-H), 2.88-3.01 (complex signal,
38 2 H, 6-H, 9-H), 4.83 (t, *J* = 5.2 Hz, 1 H, 5-H), 5.94 (broad s, 1 H, 1-NH), 6.90 (m, 1 H, 5'-
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 H), 7.82 (m, 1 H, 6'-H), 8.06 (broad s, 1 H, 3-NH). ¹³C-NMR (100.6 MHz, CDCl₃) δ: 41.4
4 (CH, C8), 41.6 (CH, C11), 43.2 (CH, C1), 43.5 (CH₂, C12), 44.6 (CH, C9), 44.9 (CH, C7),
5
6 46.3 (CH, C10), 54.8 (CH, C6), 57.0 (CH, C2), 84.1 (CH, C5), 103.1 (C, C3), 111.3 (CH,
7
8 dd, ²J_{C-F} = 17.7 Hz, ³J_{C-F} = 3.9 Hz, C5'), 115.2 (CH, m, C6'), 124.5 (C, dd, ²J_{C-F} = 8 Hz, ³J_{C-F}
9
10 = 3.5 Hz, C1'), 139.8 (C, ddd, ¹J_{C-F} = 252 Hz, ²J_{C-F} = 16.4 Hz, ²J_{C-F} = 13.7 Hz, C3'), 142.3
11
12 (C, ddd, ¹J_{C-F} = 251 Hz, ²J_{C-F} = 11.7 Hz, ³J_{C-F} = 3.2 Hz, C4'), 146.6 (C, ddd, ¹J_{C-F} = 245.8
13
14 Hz, ²J_{C-F} = 10 Hz, ³J_{C-F} = 2.7 Hz, C2'), 154.7 (C, CO). MS (DIP), m/z (%); significant ions:
15
16 348 (M⁺, 18), 173 [(C₇H₂F₃NO)⁺, 17], 159 [(C₁₁H₁₁O)⁺, 35], 147(100), 146(13), 131(24),
17
18 91(15). HRMS: Calculated for [C₁₈H₁₅F₃N₂O₂+H]⁺: 349.1158. Found: 349.1160.
19
20
21
22
23

24
25 **2-oxadamant-1-yl isocyanate, 10.** Triphosgene (940 mg, 3.16 mmol) was added in a single
26
27 portion to a solution of 2-oxadamantyl-1-amine hydrochloride (1.20 g, 6.32 mmol) in DCM
28
29 (42 mL) and saturated aqueous NaHCO₃ solution (17 mL). The resulting biphasic mixture
30
31 was stirred at room temperature for 30 min. Thereafter, the two phases were separated and
32
33 the organic layer was washed with brine, dried over anh. Na₂SO₄ and filtered. Evaporation
34
35 under vacuum below 30 °C provided isocyanate **10** as a yellow gum, which was used in the
36
37 next step without further purification.
38
39

40
41 **1-(1-acetylpiperidin-4-yl)-3-(oxadamant-1-yl)urea, 12.** Under anhydrous conditions, a
42
43 solution of isocyanate **10** (323 mg, 1.80 mmol) in anh. DCM (20 mL) was added to a solution
44
45 of 1-acetyl-4-aminopiperidine (308 mg, 2.16 mmol) in anh. DCM (10 mL), followed by
46
47 triethylamine (0.50 mL, 3.61 mmol). The reaction mixture was stirred at room temperature
48
49 overnight. The solution was then concentrated under vacuum to give an orange gum (720
50
51 mg). Purification by column chromatography (SiO₂, DCM/methanol mixtures) gave urea **12**
52
53 (300 mg, 52% yield) as a white solid. The analytical sample was obtained by washing with
54
55
56
57
58
59
60

1
2
3 pentane. Mp 172-173 °C. IR (ATR) ν : 3322, 2920, 2850, 2188, 2153, 2000, 1637, 1549,
4
5 1428, 1369, 1313, 1264, 1234, 1192, 1139, 1090, 1046, 995, 959, 879, 816, 773, 731 cm^{-1} .
6
7 $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.28-1.41 (complex signal, 2 H, 3- H_{ax} and 5- H_{ax}), 1.58-1.96
8
9 (complex signal, 9 H, 8'- H_a , 9'- H_a , 4'- H_2 , 10'- H_2 , 6'- H_2 , and 3- H_{eq} or 5- H_{eq}), 1.98-2.22
10
11 (complex signal, 6 H, COCH_3 , 8'- H_b , 9'- H_b and 5- H_{eq} or 3- H_{eq}), 2.27 [broad s, 2 H, 5'(7')-
12
13 H], 2.86 (dt, $J = 11.2$ Hz, $J' = 2.8$ Hz, 1 H, 6- H_{ax} or 2- H_{ax}), 3.18 (dt, $J = 10.8$ Hz, $J' = 2.8$ Hz,
14
15 1 H, 2- H_{ax} or 6- H_{ax}), 3.70 (dm, $J = 14$ Hz, 1 H, 2- H_{eq} or 6- H_{eq}), 3.87 (m, 1 H, 4-H), 4.27
16
17 (broad s, 1 H, 3'-H), 4.35 (broad d, $J = 14.0$ Hz, 1 H, 6- H_{eq} or 2- H_{eq}), 4.75 (s, 1 H, 3-NH),
18
19 6.06 (d, $J = 8$ Hz, 1-NH). $^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3) δ : 21.4 (CH_3 , CH_3CO), 27.9 [CH ,
20
21 $\text{C}5'(7')$], 32.1 (CH_2 , C3 or C5), 33.2 (CH_2 , C5 or C3), 34.6 (broad CH_2 , C4', C6' and C10'),
22
23 40.0 (CH_2 , C8' or C9'), 40.2 (CH_2 , C9' or C8'), 40.4 (CH_2 , C2 or C6), 45.1 (CH_2 , C6 or C2),
24
25 46.5 (CH , C4), 71.0 (CH , C3'), 80.6 (C, C1'), 156.7 (C, CO), 168.9 (C, CH_3CO). MS (DIP),
26
27 m/z (%); significant ions: 321 (M^+ , 34), 197 (32), 179 [$(\text{C}_{10}\text{H}_{13}\text{NO}_2)^+$, 34], 154 (100), 153
28
29 (18), 137 [$(\text{C}_9\text{H}_{13}\text{O})^+$, 33], 136 (32), 126 (15), 125 (51), 122 (21), 111 (17), 96 (41), 95
30
31 (18), 94 (45), 84 (19), 83 (37), 82 (54), 79 (22), 67(20), 57 (23), 56 (32), 55 (15). HRMS:
32
33 Calculated for $[\text{C}_{17}\text{H}_{27}\text{N}_3\text{O}_3+\text{H}]^+$: 322.2125. Found: 322.2124.
34
35
36
37
38
39

40 ***Trans-4-[4-(3-oxadamant-1-yl-ureido)-cyclohexyloxy]benzoic acid, 14.*** A solution of 2-
41
42 oxaadamant-1-yl isocyanate (400 mg, 2.23 mmol) in anh. DCM (25 mL) was added to a
43
44 solution of *t*-4-[(4-aminocyclohexyl)oxy]benzoic acid²⁶ (728 mg, 2.68 mmol) in anh. DCM
45
46 (12 mL), followed by triethylamine (1.24 mL, 8.94 mmol) under nitrogen. The reaction
47
48 mixture was stirred at room temperature overnight. Water (50 mL) was then added and the
49
50 phases were separated. The organic layer was extracted with further water (2 x 50 mL) and
51
52 the pH of the combined aqueous phases was adjusted to pH ~2 with 5N HCl solution, prior
53
54 extraction with DCM (3 x 50 mL). The combined organic layers were dried over anh.
55
56
57
58
59
60

1
2
3 Na₂SO₄, filtered and concentrated under vacuum yielding urea **14** (220 mg, 24% yield) as a
4
5 white solid. The analytical sample was obtained by crystallization from methanol/diethyl
6
7 ether. Mp 255-275 °C. IR (ATR) v: 3364, 3267, 3198, 3061, 2922, 2559, 2348, 2187, 2068,
8
9 2011, 1977, 1672, 1601, 1552, 1443, 1369, 1347, 1320, 1231, 1196, 1172, 1110, 1091, 1049,
10
11 1027, 989, 959, 863, 828, 774, 698, 640 cm⁻¹. ¹H-NMR (400 MHz, CD₃OD) δ: 1.37 [m, 2 H,
12
13 3'(5')-H_{ax}], 1.55 [m, 2 H, 2'(6')-H_{ax}], 1.65 [dm, *J* = 12.4 Hz, 2 H, 4''(10'')-H_a], 1.78 [dm, *J*
14
15 = 11.6 Hz, 2 H, 8''(9'')-H_a], 1.86 (complex signal, 2 H, 6''-H₂), 1.94 [m, 2 H, 4''(10'')-H_b],
16
17 2.01 [m, 2 H, 3'(5')-H_{eq}], 2.10 [m, 2 H, 2'(6')-H_{eq}], 2.22 [broad s, 2 H, 5''(7'')-H], 2.28 [dm,
18
19 *J* = 15.5 Hz, 2 H, 8''(9'')-H_b], 3.57 (m, 1 H, 4'-H), 4.18 (broad s, 1 H, 3''-H), 4.40 (m, 1 H,
20
21 1'-H), 6.92 [d, *J* = 8.8 Hz, 2 H, 3(5)-H], 7.93 [d, *J* = 8.8 Hz, 2 H, 2(6)-H]. ¹³C-NMR (100.6
22
23 MHz, CD₃OD) δ: 29.6 [CH, C5''(7'')], 31.0 [CH₂, C2'(6')], 31.4 [CH₂, C3'(5')], 35.7 [CH₂,
24
25 C4''(10'')], 35.9 (CH₂, C6''), 41.0 [CH₂, C8''(9'')], 48.6 (CH, C4'), 72.3 (CH, C3''), 75.8
26
27 (CH, C1'), 81.9 (C, C1''), 115.9 [CH, C3(5)], 126.8 (C, C1), 132.6 [CH, C2(4)], 159.0 (C,
28
29 CO), 162.4 (C, C4 and CO₂H). MS (DIP), *m/z* (%); significant ions: 414 (M⁺, 0.2), 179
30
31 [(C₁₀H₁₃NO₂)⁺, 27], 138 [(C₉H₁₄O)⁺, (C₇H₅O₃)⁺, 100], 122 (29), 121 (39), 111 (21), 108 (10),
32
33 98 (99), 96 (30), 94 (45), 82 (18), 81 (97), 79 (41), 67 (19), 65 (15), 56 (42), 55 (16). HRMS:
34
35 Calculated for [C₂₃H₃₀N₂O₅+H]⁺: 415.2227. Found: 415.2230.

36
37
38 **1-(2-Oxaadamant-1-yl)-3-(1-benzylpiperidin-4-yl)urea, 15.** To a solution of 2-
39
40 oxaadamant-1-yl isocyanate (1.25 g, 6.97 mmol) in DCM (10 mL) was added 1-
41
42 benzylpiperidin-4-amine (1.60 g, 8.37 mmol). The reaction mixture was stirred at room
43
44 temperature overnight. The solvents were evaporated under vacuum to give a yellow gum
45
46 (3.06 g). Column chromatography (DCM/methanol mixtures) gave urea **15** as a yellowish
47
48 solid (2.54 g, 82% yield). Mp 153-154 °C. IR (ATR): 694, 745, 768, 989, 110, 1194, 1225,
49
50 1319, 1372, 1441, 1484, 1540, 1664, 1918, 1959, 2918 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ:
51
52
53
54
55
56
57
58
59
60

1
2
3 1.50 [dq, $J = 3.6$ Hz, $J' = 10.4$ Hz, 2 H, 3(5)-H_a], 1.59-1.70 [complex signal, 4 H, 8'(9')-H_a,
4 4'(10')-H_a], 1.75-1.87 [complex signal, 2 H, 6'-H₂], 1.86-1.97 [complex signal, 4 H, 3(5)-H_b,
5 4'(10')-H_b], 2.13-2.22 [complex signal, 4 H, 2(6)-H_a, 8'(9')-H_b], 2.26 [broad s, 2 H, 5'(7')-
6 H], 2.74 [d, $J = 11.2$ Hz, 2 H, 2(6)-H_b], 3.49 [s, 2 H, 7-H₂], 3.71 (m, 1 H, 4-H), 4.24 (t, $J = 4$
7 Hz, 1 H, 3'-H), 4.65 (s, 1 H, 1'-NH), 6.04 (d, $J = 8.4$ Hz, 1 H, 4-NH), 7.24 (m, 1 H, 11-H),
8 7.28-7.32 (complex signal, 4 H, 9-H, 10-H, 12-H and 13-H). ¹³C-NMR (100.5 MHz, CDCl₃)
9 δ : 27.9 [CH, C5'(7')], 32.6 [CH₂, C3(5)], 34.6 [(CH₂, C4'(10'))], 34.7 (CH₂, C6'), 40.1 [(CH₂,
10 C8'(9'))], 46.2 (CH, C4), 52.1 [CH₂, C2(6)], 63.2 (CH₂, C7), 70.9 (CH, C3'), 80.6 (C, C1'),
11 126.9 (CH, C11), 128.2 [CH, C10(12) or C9(13)], 129.2 [CH, C9(13) or C10(12)], 138.2 (C,
12 C8), 156.7 (C, CO). HRMS: Calculated for [C₂₂H₃₁N₃O₂+H]⁺: 370.2489 Found: 370.2488.

13
14
15
16
17
18
19
20
21
22
23
24
25
26 **1-(2-Oxaadamant-1-yl)-3-(piperidin-4-yl)urea, 16.** To a solution of 1-(2-oxaadamant-1-
27 yl)-3-(1-benzylpiperidin-4-yl)urea (2.40 g, 6.50 mmol) in methanol (20 mL), palladium on
28 carbon 10% wt. (300 mg) and HCl 37% (1 mL) were added. The reaction mixture was
29 hydrogenated for 5 days. The palladium on carbon was filtered and the solvent was
30 evaporated under vacuum. The crude was dissolved in DCM and washed with 2N NaOH
31 solution (2 x 30 mL). The organic phase was dried over anh. Na₂SO₄ and filtered.
32 Evaporation under vacuum of the organics gave urea **16** as a white solid (1.28 g, 70% yield).
33 The product was used in the next step without further purification. The analytical sample was
34 obtained by crystallization from hot DCM (825 mg). Mp 164-165 °C. ¹H-NMR (400 MHz,
35 CDCl₃) δ : 1.37 [m, 2 H, 3(5)-H_{ax}], 1.60-1.73 [complex signal, 6 H, 4'(10')-H_a, 8'(9')-H_a],
36 1.77-1.88 (m, 2 H, 6'-H₂), 1.90-2.01 [complex signal, 4 H, 4'(10')-H_b, 3(5)-H_b], 2.19 [dm, J
37 = 12 Hz, 2 H, 8'(9')-H_b], 2.28 [broad s, 2 H, 5'(7')-H], 2.71 [ddd, 2 H, $J = 13$ Hz, $J' = 11.8$
38 Hz, $J = 2.8$ Hz, 2(6)-H_a], 3.04 [dt, 2 H, $J = 13$ Hz, $J' = 4$ Hz, 2(6)-H_b], 3.77 (m, 1 H, 4-H),
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 4.29 (broad s, 1 H, 3'-H), 4.56 (s, 1 H, 1'-NH), 6.06 (d, $J = 8.0$ Hz, 4-NH). HRMS: Calculated
4 for $[C_{15}H_{25}N_3O_2+H]^+$: 280.2020. Found: 280.2022.
5
6

7 **1-(2-Oxaadamant-1-yl)-3-(1-(4-chloro-6-methyl-1,3,5-triazin-2-yl)piperidin-4-yl)urea,**

8
9
10 **17.** To a solution of 2,4-dichloro-6-methyl-1,3,5-triazine (130 mg, 0.78 mmol) in DCM (4
11 mL) were added 1-(2-oxaadamantan-1-yl)-3-(piperidin-4-yl)urea (220 mg, 0.78 mmol) and
12 DIPEA (305 mg, 2.36 mmol). The reaction mixture was stirred at room temperature for 30
13 min. Column chromatography (DCM/methanol mixtures) gave urea **17** as a white solid (54
14 mg, 9% yield). Mp 196-197 °C. IR (ATR) ν : 708, 762, 845, 907, 964, 992, 1075, 1116, 1168,
15 1194, 1219, 1243, 1271, 1315, 1364, 1444, 1485, 1527, 1578, 1671, 1953, 1974, 1994, 2180,
16 2335, 2852, 2914 cm^{-1} . 1H -NMR (400 MHz, $CDCl_3$) δ : 1.38-1.47 [complex signal, 2 H, 3(5)-
17 H_a], 1.60-1.71 [complex signal, 4 H, 6'- H_2 and 8'(9')- H_a], 1.76-1.87 [m, 2 H, 4'(10')- H_a],
18 1.87-1.95 [m, 2 H, 4'(10')- H_b], 2.02-2.21 [complex signal, 4 H, 3(5)- H_b and 8'(9')- H_b], 2.27
19 [s, 2 H, 5'(7')-H], 2.39 (s, 3 H, CH_3), 3.16-3.24 [m, 2 H, 2(6)- H_a], 3.69 (m, 1 H, 4-H), 4.26
20 (broad s, 1 H, 3'-H), 4.55 (d, $J = 13.6$ Hz, 1 H, 2- H_b or 6- H_b), 4.63 (d, $J = 13.6$ Hz, 1 H, 6-
21 H_b or 2- H_b), 4.68 (s, 1 H, 1'-NH), 6.10 (d, $J = 7.6$ Hz, 1H, 1-NH). ^{13}C -NMR (100.5 MHz,
22 $CDCl_3$) δ : 25.4 (CH_3), 27.9 [CH, C5'(7')], 32.36 (CH_2 , C3 or C5), 32.39 (CH_2 , C5 or C3),
23 34.63 [CH_2 , C4'(10')], 34.64 (CH_2 , C6'), 40.1 (CH_2 , C8' or C9'), 40.2 (CH_2 , C9' or C8'),
24 42.4 (CH_2 , C2 or C6), 42.5 (CH_2 , C6 or C2), 46.6 (CH, C4), 71.0 (CH, C3'), 80.7 (C, C1'),
25 156.7 (C, CO), 164.1 (C, C8), 170.2 (C, C7), 177.3 (C, C9). HRMS: Calculated for
26 $[C_{19}H_{27}ClN_6O_2+H]^+$: 407.1957. Found: 407.1952.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **1-(2-Oxaadamant-1-yl)-3-(1-(4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)piperidin-4-**
50 **yl)urea, 18.** Methylamine hydrochloride (160 mg, 2.36 mmol) and DIPEA (407 mg, 3.15
51 mmol) were added to the solution of 1-(2-oxaadamantan-1-yl)-3-(1-(4-chloro-6-methyl-
52
53
54
55
56
57
58
59
60

1
2
3 1,3,5-triazin-2-yl)piperidin-4-yl)urea in DCM (5 mL) obtained in the previous step. The
4
5 reaction mixture was stirred at 40 °C for 4 hours. The solvent was evaporated under vacuum
6
7 to give a yellow gum (830 mg). Column chromatography (DCM/methanol mixtures) gave
8
9 urea **18** as a grey solid (27 mg, 8% yield). Mp 203-204 °C. IR (ATR) ν : 653, 803, 880, 993,
10
11 1085, 1118, 1189, 1235, 1317, 1366, 1442, 1532, 1644, 1943, 2143, 2337, 2843, 2920 cm^{-1} .
12
13 $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.35-1.44 [complex signal, 2 H, 3(5)- H_a], 1.61 (d, $J = 12.0$
14
15 Hz, 2 H, 6'- H_2), 1.69 [d, $J = 12.4$, 2 H, 8'(9')- H_a], 1.77-1.86 [complex signal, 2 H, 4'(10')-
16
17 H_a], 1.91 (d, $J = 10.4$ Hz, 2 H, 4'(10')- H_b], 1.99-2.04 [complex signal, 2 H, 3(5)- H_b], 2.17
18
19 [d, $J = 12.0$ Hz, 2 H, 8'(9')- H_b], 2.24-2.27 [complex signal, 5 H, 5'(7')-H and CCH_3], 2.93
20
21 (d, $J = 4.8$ Hz, 3 H, NCH_3), 3.15 [t, $J = 12.0$ Hz, 2 H, 2(6)- H_a], 3.93 (m, 1 H, 4-H), 4.25 (t, J
22
23 = 4.4 Hz, 1 H, 3'-H), 4.56 [broad s, 2 H, 2(6)- H_b], 4.73 (s, 1 H, 1'-NH), 6.09 (d, $J = 7.6$ Hz,
24
25 1 H, 1-NH). $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ : 25.2 (CH_3 , C10), 27.5 (CH_3 , C11), 27.9 [CH,
26
27 C5'(7')], 32.5 (CH_2 , C3(5)), 34.63 [CH_2 , C4'(10')], 34.66 (CH_2 , C6'), 40.1 [CH_2 , C9'(8')],
28
29 41.7 [CH_2 , C2(6)], 46.8 (CH, C4), 70.9 (CH, C3'), 80.6 (C, C1'), 156.7 (C, CO), 164.3 (C,
30
31 C8), 173.9 (C, C7), 177.3 (C, C9). HRMS: Calculated for $[\text{C}_{20}\text{H}_{31}\text{N}_7\text{O}_2+\text{H}]^+$: 402.2612.
32
33 Found: 402.2608.
34
35
36
37
38
39

40 **1-(2-Oxaadamant-1-yl)-3-(1-(tetrahydro-2H-pyran-4-carbonyl)piperidin-4-yl)urea, 19.**

41
42 To a solution of 1-(2-oxaadamant-1-yl)-3-(piperidin-4-yl)urea (150 mg, 0.53 mmol) in
43
44 EtOAc (10 mL), tetrahydro-2H-pyran-4-carboxylic acid (70 mg, 0.53 mmol), HOBt (109 mg,
45
46 0.80 mmol), EDCI·HCl (125 mg, 0.80 mmol) and triethylamine (0.15 mL, 1.07 mmol) were
47
48 added. The reaction mixture was stirred at room temperature for 24 hours. To the resulting
49
50 suspension was added water (15 mL) and the two phases were separated. The organic phase
51
52 was washed with saturated aqueous NaHCO_3 solution (15 mL) and brine (15 mL). The
53
54
55
56
57
58
59
60

combined aqueous phases were extracted with DCM (3 x 30 mL). The combined organic phases were dried over anhydrous Na_2SO_4 and filtered. Evaporation under vacuum of the organics gave urea **19** as colorless crystals (190 mg, 90% yield). Mp 150-152 °C. IR (ATR) ν : 641, 770, 878, 990, 1085, 1121, 1194, 1240, 1318, 1367, 1442, 1550, 1633, 2010, 2067, 2341, 2919 cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ : 1.30-1.39 (complex signal, 2 H, 6- H_a , 2- H_a), 1.55-1.71 [complex signal, 6 H, 4'(10')- H_a , 8'- H_a , 9'- H_a , 9- H_a , 13- H_a], 1.75-2.00 [complex signal, 7 H, 6'- H_2 , 2- H_b or 6- H_b , 4'(10')- H_b , 9- H_b , 13- H_b], 2.10 (t, $J = 13.2$ Hz, 2 H, 2- H_b or 6- H_b , 8'- H_b or 9'- H_b), 2.22 (d, $J = 12.0$ Hz, 1 H, 9'- H_b or 8'- H_b), 2.27 [broad s, 2 H, 5'(7')-H], 2.72 (tt, $J = 11.2$ Hz, $J' = 3.6$ Hz, 1 H, 8-H), 2.86 (t, $J = 11.2$ Hz, 1 H, 3- H_a or 5- H_a), 3.18 (t, $J = 11.2$ Hz, 1 H, 5- H_a or 3- H_a), 3.43 [td, $J = 12.0$ Hz, $J' = 2$ Hz, 2 H, 10(12)- H_a], 3.80 (d, $J = 14.0$ Hz, 1 H, 5- H_b or 3- H_b), 3.88 (m, 1 H, 4-H), 4.00 [d, $J = 11.2$ Hz, 2 H, 10(12)- H_b], 4.27 (t, $J = 3.6$ Hz, 1 H, 3'-H), 4.38 (dm, $J = 13.6$ Hz, 1 H, 3- H_b or 5- H_b), 4.75 (s, 1 H, 1'-NH), 6.07 (d, $J = 8.0$ Hz, 1 H, 4-NH). $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ : 27.9 [CH, C5'(7')], 29.08 (CH_2 , C9 or C13), 29.14 (CH_2 , C13 or C9), 32.2 (CH_2 , C2 or C6), 33.6 (CH_2 , C6 or C2), 34.59 (CH_2 , C6'), 34.61 [CH_2 , C4'(10')], 37.6 (CH, C8), 40.0 (CH_2 , C8' or C9'), 40.2 (CH_2 , C9' or C8'), 40.7 (CH_2 , C3 or C5), 44.0 (CH_2 , C5 or C3), 46.7 (CH, C4), 67.2 [CH_2 , C10(12)], 71.0 (CH, C3'), 80.7 (C, C1'), 156.7 (C, $\underline{\text{CO}}$), 172.7 ($\underline{\text{COR}}$). HRMS: Calculated for $[\text{C}_{21}\text{H}_{33}\text{N}_3\text{O}_4+\text{H}]^+$: 392.2544. Found: 392.2553.

1-(2-Oxaadamant-1-yl)-3-(1-nicotinoylpiperidin-4-yl)urea, 20. To a solution of 1-(2-oxaadamant-1-yl)-3-(piperidin-4-yl)urea (150 mg, 0.53 mmol) in EtOAc (10 mL), nicotinic acid (66 mg, 0.53 mmol), HOBt (109 mg, 0.805 mmol), EDCI·HCl (125 mg, 0.80 mmol) and triethylamine (0.15 mL, 1.07 mmol) were added. The reaction mixture was stirred at room temperature for 24 hours. Water (15 mL) was added to the resulting suspension and the two

1
2
3 phases were separated. The organic phase was washed with saturated aqueous NaHCO₃
4 solution (15 mL) and brine (15 mL). The combined aqueous phases were basified with 1N
5 NaOH solution (30 mL) and extracted with DCM (3 x 30 mL). The combined organic phases
6 were dried over anh. Na₂SO₄ and filtered. Evaporation under vacuum of the organics gave a
7 white solid (140 mg). Column chromatography (DCM/methanol mixtures) gave pure urea **20**
8 as a white solid (63 mg, 32% yield). Mp 187-188 °C. IR (ATR) v: 618, 711, 736, 767, 824,
9 990, 1114, 1132, 1194, 1219, 1245, 1269, 1318, 1367, 1436, 1483, 1537, 1622, 1666, 2051,
10 2144, 2217, 2919 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ: 1.37 (m, 1 H, 5-H_a or 3-H_a), 1.51 (m,
11 1 H, 3-H_a or 5-H_a), 1.60-1.72 [complex signal, 4 H, 8'(9')-H_a and 6'-H₂], 1.82 [m, 2 H,
12 4'(10')-H_a], 1.92 (d, *J* = 12.4 Hz, 2 H, 3-H_b and 5-H_b), 1.97-2.09 [complex signal, 2 H,
13 4'(10')-H_b], 2.15 [broad s, 2 H, 8'(9')-H_b], 2.27 [broad s, 2 H, 5'(7')-H], 3.02-3.28 [complex
14 signal, 2 H, 2(6)-H_a], 3.57-3.75 (complex signal, 1 H, 2-H_b or 6-H_b), 3.93 (m, 1 H, 4-H), 4.29
15 (t, *J* = 4.4 Hz, 1 H, 3'-H), 4.50 (m, 1 H, 6-H_b or 2-H_b), 4.80 (s, 1 H, 1'-NH), 6.12 (d, *J* = 7.6
16 Hz, 1 H, 4-NH), 7.31-7.40 (dd, *J* = 8.0 Hz, *J'* = 4.4 Hz, 1 H, 10-H), 7.74 (d, *J* = 8.0 Hz, 1 H,
17 9-H), 8.66 (complex signal, 2 H, 11-H, 13-H). ¹³C-NMR (100.5 MHz, CDCl₃) δ: 27.9 [CH,
18 C5'(7')], 32.2 (CH₂, C3 or C5), 33.3 (CH₂, C5 or C3), 34.60 (CH₂, C6'), 34.63 [CH₂,
19 C4'(10')], 40.1 (CH₂, C8'(9')), 41.3 (CH₂, C2 or C6), 46.6 (CH, C4 and CH₂, C6 or C2),
20 71.0 (CH, C3'), 80.7 (C, C1'), 123.5 (C, C10), 131.7 (C, C8), 134.8 (C, C9), 147.7 (C, C11
21 or C13), 150.7 (C, C13 or C11), 156.7 (C, C=O), 167.7 (C, C=O). HRMS: Calculated for
22 [C₂₁H₂₈N₄O₃+H]⁺: 385.2234. Found: 385.2238.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 **1-(2-Oxaadamant-1-yl)-3-(1-(2-fluorobenzoyl)piperidin-4-yl)urea, 21.** To a solution of
50 1-(2-oxaadamant-1-yl)-3-(piperidin-4-yl)urea (120 mg, 0.43 mmol) in EtOAc (10 mL), 2-
51 fluorobenzoic acid (61 mg, 0.43 mmol), HOBt (87mg, 0.64 mmol), EDCI·HCl (100 mg,
52
53
54
55
56
57
58
59
60

0.64 mmol) and triethylamine (0.12 mL, 0.86 mmol) were added. The reaction mixture was stirred at room temperature for 24 hours. Water (15 mL) and DCM (20 mL) were added to the resulting suspension and the two phases were separated. The organic phase was washed with saturated aqueous NaHCO₃ solution (15 mL), brine (15 mL), dried over anh. Na₂SO₄ and filtered. Evaporation under vacuum of the organics gave urea **21** as a white solid (131 mg, 77% yield). The analytical sample was obtained as a white solid (111 mg) by crystallization from hot EtOAc. Mp 193-194 °C. IR (ATR) ν : 630, 785, 925, 987, 1010, 1093, 1121, 1191, 1243, 1318, 1372, 1447, 1462, 1491, 1555, 1615, 1684, 1974, 2351, 2925, 3338 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ : 1.38 (broad s, 1 H, 5-H_a or 3-H_a), 1.45-1.54 (m, 1 H, 3-H_a or 5-H_a), 1.61-1.71 (complex signal, 4 H, 6'-H₂, 8'-H_a, 9'-H_a), 1.82 [m, 2 H, 4'(10')-H_a], 1.90-1.99 [complex signal, 3 H, 5-H_b or 3-H_b, 4'(10')-H_b], 2.06 (m, 1 H, 3-H_b or 5-H_b), 2.13 (m, 1 H, 9-H_b or 8-H_b), 2.20 (dq, $J = 12.4$ Hz, $J' = 2.0$ Hz, 1 H, 8'-H_b or 9'-H_b), 2.27 [s, 2 H, 5'(7')-H], 3.06-3.19 (complex signal, 2 H, 2-H_a, 6-H_a), 3.5 (d, $J = 13.6$ Hz, 1 H, 2-H_b or 6-H_b), 3.92 (m, 1 H, 4-H), 4.29 (s, 1 H, 3'-H), 4.53 (dm, $J = 13.6$ Hz, 1 H, 6-H_b or 2-H_b), 4.74 (s, 1 H, 1'-NH), 6.09 (d, $J = 7.6$ Hz, 1 H, 4-NH), 7.08 (m, 1 H, 10-H), 7.19 (td, $J = 7.6$ Hz, $J' = 1.2$ Hz, 1 H, 13-H), 7.34-7.41 (complex signal, 2 H, 11-H, 12-H). ¹³C-NMR (100.5 MHz, CDCl₃) δ : 27.95 (CH, C5' or C7'), 27.97 (CH, C7' or C5'), 32.2 (CH₂, C3 or C5), 33.1 (CH₂, C5 or C3), 34.7 [CH₂, C6' and C4'(10')], 40.1 (CH₂, C8' or C9'), 40.2 (CH₂, C9' or C8'), 40.8 (CH₂, C6 or C2), 45.9 (CH₂, C2 or C6), 46.6 (CH, C4), 71.0 (CH, C3'), 80.7 (C, C1'), 115.7 (CH, d, $^2J_{C-F} = 21.4$ Hz, C10), 124.2 (C, d, $^2J_{C-F} = 17.9$ Hz, C8), 124.7 (CH, d, $^4J_{C-F} = 3.5$ Hz, C13), 129.0 (CH, d, $^3J_{C-F} = 3.8$ Hz, C11), 131.2 (CH, d, $^3J_{C-F} = 7.9$ Hz, C12), 156.7 (C, CO), 158.1 (C, d, $^1J_{C-F} = 247.3$ Hz, C9), 165.2 (C, COR). HRMS: Calculated for [C₂₂H₂₈FN₃O₃+H]⁺: 402.2187. Found: 402.2187.

1-(2-Oxaadamant-1-yl)-3-(1-(isopropylsulfonyl)piperidin-4-yl)urea, 22. To a solution of 1-(oxaadamant-1-yl)-3-(piperidin-4-yl)urea (250 mg, 0.895 mmol) in DCM (10 mL), triethylamine (0.15 mL, 1.07 mmol) was added. The mixture was cooled down with an ice bath (0 °C) and propane-2-sulfonyl chloride (127 mg, 0.89 mmol) was added dropwise. The reaction mixture was stirred at room temperature overnight and quenched by the addition of HCl solution 37% (2 mL). The organic phase was collected, and the aqueous layer was extracted with EtOAc (4 x 30 mL). The combined organic phases were dried over anh. Na₂SO₄ and filtered. Evaporation of the organics gave an oil that was then dissolved in DCM (20 mL) and washed with 2N NaOH solution (3 x 20 mL). The organic phase was dried over anh. Na₂SO₄ and filtered. Evaporation under vacuum of the organics gave **22** as a white solid (88 mg, 26% yield). The analytical sample was obtained by crystallization from hot DCM as a white solid (60 mg). Mp 190-191 °C. IR (ATR) ν : 618, 729, 842, 884, 935, 961, 1010, 1041, 1093, 1116, 1132, 1196, 1243, 1269, 1292, 1320, 1374, 1444, 1547, 1635, 2930, 3333 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ : 1.32 [d, J = 6.8 Hz, 6 H, 8(9)-H], 1.50 [dq, J = 4.0 Hz, J' = 11.2 Hz, 2 H, 3(5)-H_a], 1.63 [d, J = 12.0 Hz, 2 H, 4'(10')-H_a], 1.69 [d, J = 12.4, 2 H, 8'(9')-H_a], 1.82 (complex signal, 2 H, 6'-H₂), 1.92 [d, J = 12.0 Hz, 2 H, 4'(10')-H_b], 2.0 [broad d, J = 13.2 Hz, 2 H, 3(5)-H_b], 2.16 [d, J = 11.2 Hz, 2 H, 8'(9')-H_b], 2.27 [broad s, 2 H, 5'(7')-H], 3.01 [ddd, J = 2.4 Hz, J' = J'' = 13.6 Hz, 2 H, 2(6)-H_a], 3.17 (sept, 1 H, 7-H), 3.75 [dm, J = 13.2 Hz, 2 H, 2(6)-H_b], 3.81 (m, 1 H, 4-H), 4.28 (t, J = 4.4 Hz, 1 H, 3'-H), 4.74 (s, 1 H, 1'-NH), 6.08 (d, J = 8.0 Hz, 1 H, 4-NH). ¹³C-NMR (100.5 MHz, CDCl₃) δ : 16.7 [CH₃, C8(9)], 27.9 [CH, C5'(7')], 33.1 [CH₂, C3(5)], 34.61 [CH₂, C4'(10')], 34.63 (CH₂, C6'), 40.1 [CH₂, C8'(9')], 45.4 [CH₂, C2(6)], 46.3 (CH, C4), 53.4 (CH, C7), 71.0 (CH, C3'), 80.6 (C, C1'), 156.7 (C, CO). HRMS: Calculated for [C₁₈H₃₁N₃O₄S+H]⁺: 386.2108. Found: 386.2113.

1
2
3 **1-(2-Oxaadamant-1-yl)-3-(1-(cyclopropanecarbonyl)-piperidin-4-yl)urea, 23.** To a
4 solution of 1-(2-oxaadamant-1-yl)-3-(piperidin-4-yl)urea (300 mg, 1.07 mmol) in DCM (10
5 mL), cyclopropanecarbonyl chloride (112 mg, 1.07 mmol) and triethylamine (0.18 mL, 1.29
6 mmol) were added. The reaction mixture was stirred at room temperature overnight and
7 quenched by the addition of aqueous HCl 37% solution (3 mL). The organic phase was
8 collected, and the aqueous phase was extracted with EtOAc (4 x 10 mL). The combined
9 organic phases were washed with NaOH 2N (2 x 30 mL), dried over anhydrous Na₂SO₄ and filtered.
10 Evaporation under vacuum of the organics gave urea **23** as a yellow oil (382 mg, 48% yield).
11 The analytical sample was obtained as a white solid (180 mg) by crystallization from hot
12 EtOAc. Mp 197-198 °C. IR (ATR) ν: 612, 729, 816, 876, 922, 961, 992, 1085, 1132, 1191,
13 1219, 1266, 1310, 1369, 1447, 1555, 1604, 1640, 2925, 3307 cm⁻¹. ¹H-NMR (400 MHz,
14 CDCl₃) δ: 0.73 [m, 2 H, 9(10)-H_a], 0.95 [m, 2 H, 9(10)-H_b], 1.32-1.46 (complex signal, 2 H,
15 3-H_a, 5-H_a), 1.60-1.71 (complex signal, 4 H, 6'-H₂, 8'-H_a, 9'-H_a), 1.74 (m, 1 H, 8-H), 1.79-
16 1.97 [complex signal, 5 H, 3-H_b or 5-H_b and 4'(10')-H₂], 2.05-2.21 (complex signal, 3 H, 5-
17 H_b or 3-H_b and 9'-H_b, 8'-H_b), 2.27 [broad s, 2 H, 5'(7')-H], 2.90 (t, *J* = 12.4 Hz, 1 H, 6-H_a
18 or 2-H_a), 3.27 (t, *J* = 11.6 Hz, 1 H, 2-H_a or 6-H_a), 3.90 (m, 1 H, 4-H), 4.07 (m, 1 H, 2-H_b or
19 6-H_b), 4.27 (t, *J* = 4.4 Hz, 1 H, 3'-H), 4.35 (m, 1 H, 6-H_b or 2-H_b), 4.80 (broad s, 1 H, 1'-
20 NH), 6.08 (d, *J* = 8.0 Hz, 1 H, 4-NH). ¹³C-NMR (100.5 MHz, CDCl₃) δ: 7.3 [CH₂, C9(10)],
21 10.9 (CH, C8), 27.9 [CH, C5'(7')], 32.2 (CH₂, C3 or C5), 33.4 (CH₂, C5 or C3), 34.6 [CH₂,
22 C6' and C4'(10')], 40.0 (CH₂, C9' or C8'), 40.2 (CH₂, C8' or C9'), 41.2 (CH₂, C6 or C2),
23 44.3 (CH₂, C2 or C6), 46.8 (CH, C4), 71.0 (CH, C3'), 80.7 (C, C1'), 156.8 (C, C=O), 171.9
24 (C, C=O). HRMS: Calculated for [C₁₉H₂₉N₃O₃+H]⁺: 348.2282. Found: 348.2289.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **1-(2-Oxaadamantan-1-yl)-3-(1-propionylpiperidin-4-yl)urea, 24.** To a solution of 2-
54 oxaadamantan-1-yl isocyanate (2.11 mmol) in DCM (5 mL) was added 1-(4-aminopiperidin-1-
55
56
57

60

1
2
3 yl)propan-1-one (330 mg, 2.11 mmol). The reaction mixture was stirred at room temperature
4
5 overnight. The solvent was evaporated under vacuum to give a yellow gum (823 mg).
6
7 Column chromatography (DCM/methanol mixtures) gave the urea **24** as a white solid (280
8
9 mg, 40% yield). Mp 165-166 °C. The analytical sample was obtained by crystallization from
10
11 hot EtOAc. IR (ATR) ν : 887, 930, 965, 995, 1011, 1092, 1119, 1137, 1195, 1218, 1247, 1267,
12
13 1321, 1375, 1444, 1556, 1620, 1647, 2332, 2367, 2852, 2927, 3336 cm^{-1} . $^1\text{H-NMR}$ (400
14
15 MHz, CDCl_3) δ 1.13 (t, $J = 7.6$ Hz, 3 H, CH_3), 1.28-1.40 (complex signal, 2 H, 3- H_a , 5- H_a),
16
17 1.60-1.70 [complex signal, 4 H, 9'- H_a , 8'- H_a , 4'(10')- H_a], 1.75-1.87 (m, 2 H, 6'- H_2), 1.87-
18
19 1.97 [complex signal, 3 H, 4'(10')- H_b , 3- H_b or 5- H_b], 2.04 (dm, $J = 12.8$ Hz, 1 H, 5- H_b or 3-
20
21 H_b), 2.09-2.22 (complex signal, 2 H, 9'- H_b , 8'- H_b), 2.27 [broad s, 2 H, 5'(7')-H], 2.33 (q, J
22
23 = 7.6 Hz, 2 H, CH_2CH_3), 2.87 (m, 1 H, 6- H_a or 2- H_a), 3.15 (m, 1 H, 2- H_a or 6- H_a), 3.74 (dm,
24
25 $J = 13.6$ Hz, 1 H, 2- H_b or 6- H_b), 3.87 (m, 1 H, 4-H), 4.26 (t, $J = 4.0$ Hz, 1 H, 3'-H), 4.37 (dm,
26
27 $J = 13.6$ Hz, 1 H, 6- H_b or 2- H_b), 4.72 (s, 1 H, 1'-NH), 6.06 (d, $J = 8.0$ Hz, 1 H, 4-NH). $^{13}\text{C-}$
28
29 NMR (100.5 MHz, CDCl_3) δ : 9.5 (CH_3 , CH_2CH_3), 26.5 (CH_2 , CH_2CH_3), 27.9 [CH , C5'(7')],
30
31 32.2 (CH_2 , C3 or C5), 33.3 (CH_2 , C5 or C3), 34.6 [CH_2 , C6', C4'(10')], 40.0 (CH_2 , C9' or
32
33 C8'), 40.2 (CH_2 , C8' or C9'), 40.5 (CH_2 , C6 or C2), 44.1 (CH_2 , C2 or C6), 46.6 (CH , C4),
34
35 71.0 (CH , C3'), 80.6 (C, C1'), 156.7 (C, CO), 172.2 (C, COR). HRMS: Calculated for
36
37 $[\text{C}_{18}\text{H}_{29}\text{N}_3\text{O}_3+\text{H}]^+$: 336.2282 Found: 336.2274.

38
39
40
41
42
43
44 **1-(1-(4-Acetylphenyl)piperidin-4-yl)-3-(2-oxaadamant-1-yl)urea, 25.** To a solution of 2-
45
46 oxaadamant-1-yl isocyanate (188 mg, 1.05 mmol) in DCM (5 ml), 1-(4-(4-aminopiperidin-
47
48 1-yl)phenyl)ethan-1-one³⁶ (230 mg, 1.05 mmol) and triethylamine (0.15 mL, 1.05 mmol)
49
50 were added. The reaction mixture was stirred at room temperature overnight. The solvents
51
52 were evaporated under vacuum to give an orange solid (410 mg). Column chromatography
53
54 (DCM/methanol mixtures) gave the urea **25** as a white solid (183 mg, 45% yield). Mp 190-
55
56
57
58
59
60

1
2
3 191 °C. IR (ATR) ν : 674, 723, 770, 819, 866, 915, 953, 974, 995, 1111, 1134, 1194, 1222,
4
5 1279, 1315, 1330, 1475, 1537, 1597, 1653, 1992, 2160, 2341, 2930 cm^{-1} . $^1\text{H-NMR}$ (400
6
7 MHz, CDCl_3) δ : 1.53 [dq, $J = 4.0$ Hz, $J' = 12.8$ Hz, 2 H, 3(5)- H_a], 1.59-1.64 (complex signal,
8
9 2 H, 6'- H_2), 1.69 [dm, $J = 12.0$ Hz, 2 H, 9'(8')- H_a], 1.77-1.94 [complex signal, 4 H, 4'(10')-
10
11 H_2], 2.06 [dm, $J = 12.8$ Hz, 2 H, 3(5)- H_b], 2.17 [dm, $J = 12.4$ Hz, 2 H, 9'(8')- H_b], 2.27 [broad
12
13 s, 2 H, 5'(7')-H], 2.50 (s, 3 H, COCH_3), 3.08 [ddd, $J = 2.6$ Hz, $J' = 11.2$ Hz, $J'' = 13.6$ Hz, 2
14
15 H, 2(6)- H_a], 3.78 [dt, $J = 13.6$ Hz, $J' = 4.0$ Hz, 2 H, 2(6)- H_b], 3.92 (m, 1 H, 4-H), 4.26 (broad
16
17 s, 1 H, 3'-H), 4.74 (s, 1 H, 1'-NH), 6.07 (d, $J = 7.6$ Hz, 1 H, 4-NH), 6.86 [d, $J = 9.2$ Hz, 2 H,
18
19 9(11)-H], 7.85 [d, $J = 9.2$ Hz, 2 H, 8(12)-H]. $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3) δ : 26.0 (CH_3 ,
20
21 C13), 27.9 [CH, C5'(7')], 32.0 [CH_2 , C3(5)], 34.6 [CH_2 , C6' and C4'(10')], 40.1 [CH_2 ,
22
23 C9'(8')], 46.57 (CH, C4), 46.59 [CH_2 , C2(6)], 71.0 (CH, C3'), 80.6 (C, C1'), 113.4 [CH,
24
25 C9(11)], 127.1 (C, C10), 130.5 [CH, C8(12)], 153.7 (C, C7), 156.7 (C, CO), 196.3 (C,
26
27 COCH_3). HRMS: Calculated for $[\text{C}_{23}\text{H}_{31}\text{N}_3\text{O}_3+\text{H}]^+$: 398.2438. Found: 398.2448.
28
29
30
31
32

33 **1-(2-Oxadmantan-1-yl)-3-(1-(methylsulfonyl)piperidin-4-yl)urea, 26.** To a solution of
34
35 1-amino-2-oxa-adamantane hydrochloride (265 mg, 1.4 mmol) in DCM (6 mL) and saturated
36
37 aqueous NaHCO_3 solution (6 mL) was added triphosgene (153 mg, 0.52 mmol). The biphasic
38
39 mixture was stirred at room temperature for 30 min and then the two phases were separated
40
41 and the organic layer was washed with brine (5 mL), dried over anh. Na_2SO_4 , filtered and
42
43 evaporated under vacuum to obtain 1-2 mL of a solution of the isocyanate in DCM. 1-
44
45 (methylsulfonyl)piperidin-4-amine was suspended in anh. THF (10 mL) under argon
46
47 atmosphere and the mixture was cooled down to -78 °C. Then, *n*-butyllithium (2.5 M in
48
49 hexanes, 0.73 mL, 1.82 mmol) was added dropwise during 20 min. Meanwhile, the
50
51 isocyanate from the previous step was dissolved in anh. THF and cooled down to 0 °C. The
52
53 deprotonated amine was then tempered to 0 °C and the solution of isocyanate in THF was
54
55
56
57
58
59
60

1
2
3 added. The mixture was stirred at room temperature overnight. The reaction was quenched
4
5 by the addition of methanol (5 mL) and the solvent was evaporated to obtain a yellow gum
6
7 (707 mg). Column chromatography (DCM/methanol mixtures) gave urea **26** as a white solid
8
9 (47 mg, 10% yield). Mp 213-214 °C. IR (NaCl disk) ν : 629, 667, 729, 772, 824, 849, 885,
10
11 929, 954, 960, 968, 993, 1012, 1042, 1052, 1095, 1118, 1142, 1159, 1203, 1246, 1272, 1293,
12
13 1334, 1355, 1376, 1446, 1466, 1562, 1637, 2850, 2922, 3323 cm^{-1} . $^1\text{H-NMR}$ (400 MHz,
14
15 CDCl_3), δ : 1.54 [m, 2 H, 3(5)- H_a], 1.63 [d, $J = 12.4$ Hz, 2 H, 4'(10')- H_a], 1.70 [d, $J = 12.0$
16
17 Hz, 2 H, 9'(8')- H_a], 1.81 (m, 2 H, 6'- H_2), 1.91 [dm, $J = 11.2$ Hz, 2 H, 4'(10')- H_b], 2.06 [ddm,
18
19 $J = 12.8$ Hz, $J' = 3.6$ Hz, 2 H, 3(5)- H_b], 2.15 [d, $J = 11.6$ Hz, 2 H, 9'(8')- H_b], 2.27 [broad s,
20
21 $J = 3.2$ Hz, 2 H, 5'(7')-H], 2.77 (s, 3 H, 7-H), 2.82 [ddd, $J = J' = 12.0$ Hz, $J'' = 2.8$ Hz, 2 H,
22
23 2(6)- H_a], 3.70 [dm, $J = 12.0$ Hz, 2 H, 2(6)- H_b], 3.77 (m, 1 H, 4-H), 4.27 (t, $J = 4.4$ Hz, 1 H,
24
25 3'-H), 4.82 (s, 1 H, 1'-NH), 6.06 (d, $J = 8.0$ Hz, 1 H, 4-NH). $^{13}\text{C-NMR}$ (100.5 MHz, CDCl_3)
26
27 δ : 27.9 [CH, C5'(7')], 32.2 (CH_2 , C3(5)), 34.6 [CH_2 , C4'(10') and C6'], 34.9 (CH_3 , C7), 40.1
28
29 (CH_2 , C9'(8')), 45.0 [CH_2 , C2(6)], 46.1 (CH, C4), 71.0 (CH, C3'), 80.7 (C, C1'), 156.7 (C,
30
31 CO). HRMS: Calculated for $[\text{C}_{16}\text{H}_{27}\text{N}_3\text{O}_4\text{S}+\text{H}]^+$: 358.1795. Found: 358.1803.

32
33
34
35
36
37 **1-(2-Oxaadamantan-1-yl)-3-(benzo[d]thiazol-2-yl)urea, 27.** 2-Amino-1,3-benzothiazole
38
39 (114 mg, 0.76 mmol) was dissolved in anh. THF (7 mL) under argon and cooled to -78 °C
40
41 on a dry ice in acetone bath. Then, *n*-butyllithium (2.5 M in hexanes, 0.31 mL, 0.76 mmol)
42
43 was added dropwise during 20 min. Afterwards, the reaction mixture was removed from the
44
45 dry ice in acetone bath and tempered to 0 °C with an ice bath. Meanwhile, 2-oxaadamant-1-
46
47 yl isocyanate (150 mg, 0.84 mmol) was dissolved in anh. THF (4 mL) under argon and was
48
49 continuously added to the reaction mixture. The mixture was stirred at room temperature
50
51 overnight. Methanol (3 mL) was added to quench any unreacted *n*-butyllithium. The
52
53 precipitate formed was filtered and washed with ice-cold THF to afford urea **27** as a white
54
55
56
57

1
2
3 solid (151 mg, 42% overall yield). Mp 240 °C (dec). IR (ATR) ν : 731, 757, 788, 822, 866,
4
5 884, 920, 964, 995, 1046, 1093, 1119, 1191, 1248, 1274, 1323, 1341, 1377, 1452, 1514,
6
7 1537, 1597, 1718, 1904, 1992, 2036, 2134, 2201, 2852, 2894, 2930, 3064, 3255, 3322 cm^{-1} .
8
9 $^1\text{H-NMR}$ (400 MHz, DMSO) δ : 1.57 [dm, $J = 12.0$ Hz, 2 H, 4'(10')-H_a], 1.73-1.98 [complex
10
11 signal, 6 H, 4'(10')-H_b, 6'-H₂, 8'(9')-H_a], 2.18 [m, 2 H, 5'(7')-H], 2.23 [dm, $J = 12.4$ Hz, 2
12
13 H, 8'(9')-H_b], 4.11 (m, 1 H, 3'-H), 7.16 (ddd, $J = 8.0$ Hz, $J' = 8.0$ Hz, $J'' = 1.2$ Hz, 1 H, 5-H
14
15 or 6-H), 7.27 (ddd, $J = 8.0$ Hz, $J' = 7.2$ Hz, $J'' = 1.2$ Hz, 1 H, 6-H or 5-H), 7.58 (dm, $J = 7.6$
16
17 Hz, 1 H, 7-H), 7.79-7.86 (complex signal, 2 H, 4-H, 1'-NH or 2-NH). $^{13}\text{C-NMR}$ (100.5 MHz,
18
19 DMSO) δ : 27.7 [CH, C5'(7')], 34.46 [CH₂, C4'(10')], 34.48 (CH₂, C6'), 39.5 [CH₂, C8'(9')],
20
21 69.3 (CH, C3'), 80.5 (C, C1'), 118.7 (CH, C7), 120.9 (CH, C4), 121.3 [(CH, C5 or C6), (C,
22
23 C7a)], 125.1 (CH, C6 or C5), 131.2 [(C, C2), (C, C3_a)], 149.4 (C, CO). HRMS: Calculated
24
25 for [C₁₇H₁₉N₃O₂S+H]⁺: 330.1271. Found: 330.1272.

26
27
28
29
30
31 **1-(-2-Oxaadamantan-1-yl)-3-(isoxazol-3-yl)urea, 28.** 3-Aminoisoxazole (103 mg, 1.22
32
33 mmol) was dissolved in anh. THF (13 mL) under argon and cooled to -78 °C on a dry ice in
34
35 acetone bath. Then, *n*-butyllithium (2.5 M in hexanes, 0.50 mL, 1.22 mmol) was added
36
37 dropwise during 20 min. Afterwards, the reaction mixture was removed from the dry ice in
38
39 acetone bath and tempered to 0 °C with an ice bath. Meanwhile, 2-oxaadamant-1-yl
40
41 isocyanate (258 mg, 1.34 mmol) was dissolved in anh. THF (6 mL) under argon and was
42
43 continuously added to the reaction mixture. The mixture was stirred at room temperature
44
45 overnight. Methanol (4.5 mL) was added to quench any unreacted *n*-butyllithium. The
46
47 organic solvents were evaporated under vacuum to give an orange gum (371 mg). Column
48
49 chromatography (hexane/EtOAc mixtures) gave urea **28** as a white solid (90 mg, 22% overall
50
51 yield). Mp 193 °C. IR (ATR) ν : 768, 788, 824, 888, 929, 959, 965, 987, 1014, 1050, 1075,
52
53
54
55
56
57
58
59
60

1
2
3 1093, 1116, 1196, 1260, 1288, 1324, 1377, 1395, 1444, 1475, 1566, 1598, 1672, 1685, 1920,
4
5 2005, 2051, 2158, 2215, 2323, 2369, 2851, 2923, 3082, 3179, 3287 cm⁻¹. ¹H-NMR (400
6
7 MHz, CDCl₃) δ: 1.64 [dm, *J* = 11.8 Hz, 2 H, 4'(10')-H_a], 1.77-1.96 [complex signal, 4 H, 6'-
8
9 H₂, 8'(9')-H_a], 2.03 [dm, *J* = 11.8 Hz, 2 H, 4'(10')-H_b], 2.25 [dm, *J* = 12.4 Hz, 2 H, 8'(9')-
10
11 H_b], 2.30 [m, 2 H, 5'(7')-H], 4.34 (m, 1 H, 3'-H), 6.11 (broad s, 1'-NH), 6.75 (s, 1 H, 4-H),
12
13 8.19 (d, *J* = 1.6 Hz, 1 H, 5-H), 8.95 (broad s, 1 H, 3-NH). ¹³C-NMR (100.5 MHz, CDCl₃) δ:
14
15 28.0 [CH, C5'(7')], 34.55 [CH₂, C4'(10')], 34.58 (CH₂, C6'), 40.2 [CH₂, C8'(9')], 71.2 (CH,
16
17 C3'), 81.2 (C, C1'), 98.7 (CH, C4), 153.6 (C, C3), 158.2 [(C, CO), (CH, C5)]. HRMS:
18
19 Calculated for [C₁₃H₁₇N₃O₃+H]⁺: 264.1343. Found: 264.1345.
20
21
22
23

24 **1-(2-Oxaadamantan-1-yl)-3-(1,3,5-triazin-2-yl)urea, 29.** 2-Amino-1,3,5-triazine (245
25
26 mg, 2.55 mmol) was dissolved in anh. THF (20 mL) under argon and cooled to -78 °C on a
27
28 dry ice in acetone bath. Then, *n*-butyllithium (2.5 M in hexanes, 1.05 mL, 2.55 mmol) was
29
30 added dropwise during 20 min. Afterwards, the reaction mixture was removed from the dry
31
32 ice in acetone bath and tempered to 0 °C with an ice bath. Meanwhile, 2-oxaadamant-1-yl
33
34 isocyanate (539 mg, 2.80 mmol) was dissolved in anh. THF (8 mL) under argon and was
35
36 continuously added to the reaction mixture. The mixture was stirred at room temperature
37
38 overnight. Methanol (9 mL) was added to quench any unreacted *n*-butyllithium. A white
39
40 precipitate formed among the orange solution was filtered and washed with ice-cold THF to
41
42 afford urea **29** as a white solid (340 mg, 35% overall yield). Mp 157-158 °C. IR (ATR) ν:
43
44 700, 783, 824, 887, 965, 997, 1080, 1117, 1186, 1194, 1270, 1320, 1343, 1372, 1395, 1402,
45
46 1480, 1482, 1502, 1590, 1625, 1700, 2000, 2055, 2170, 2260, 2345, 2546, 2847, 2922, 3233,
47
48 3383, 3498 cm⁻¹. ¹H-NMR (400 MHz, DMSO) δ: 1.54 [dm, *J* = 12.0 Hz, 2 H, 4'(10')-H_a],
49
50 1.66-1.98 [complex signal, 6 H, 4'(10')-H_b, 6'-H₂, 8'(9')-H_a], 2.15 [m, 2 H, 5'(7')-H], 2.26
51
52
53
54
55
56
57
58
59
60

1
2
3 [dm, $J = 12.0$ Hz, 2 H, 8'(9')-H_b], 4.05 (m, 1 H, 3'-H), 7.31 (broad s, 1 H, 2-NH), 8.34 (s, 2
4 H, 4-H, 6-H). ¹³C-NMR (100.5 MHz, DMSO) δ : 27.7 [CH, C5'(7')], 34.60 [CH₂, C4'(10')],
5 34.63 (CH₂, C6'), 39.6 (CH₂, C8'(9')), 69.1 (CH, C3'), 80.1 (C, C1'), 164.7 (C, CO), 165.2
6 [(CH, C4, C6), (C, C2)]. HRMS: Calculated for [C₁₃H₁₇N₅O₂+H]⁺: 276.1455. Found:
7 276.1454.
8
9

10
11
12
13
14 **1-(2-Oxaadamant-1-yl)-3-(3-chloro-5-trifluoromethoxy)phenyl)urea, 30.** A solution of
15 3-chloro-5-(trifluoromethoxy)aniline (200 mg, 0.94 mmol) in toluene (3 mL) was treated
16 with triphosgene (140 mg, 0.47 mmol). Immediately, triethylamine (0.13 mL, 0.94 mmol)
17 was added and the reaction mixture was stirred at 70 °C for 2 hours. Afterwards, pentane (0.5
18 mL) was added and a white precipitate was formed. The mixture was filtered and pentane
19 was evaporated under vacuum at room temperature to give the isocyanate in toluene solution
20 that was used in the next step without further purification. To a solution of 3-
21 (trifluoromethoxy)-5-chlorophenylisocyanate from the previous step were added DCM (5
22 mL), 2-oxaadamantan-1-amine hydrochloride (161 mg, 0.85 mmol) and triethylamine (0.24
23 mL, 1.71 mmol). The suspension was stirred at room temperature overnight. The mixture
24 was evaporated under vacuum to give a residue that was then dissolved in DCM (20 mL) and
25 washed with 2N HCl solution. The organic phase was dried over anh. Na₂SO₄ and filtered.
26 Evaporation under vacuum of the organics gave urea **30** (284 mg, 89% overall yield) as an
27 orange solid. The analytical sample was obtained as a white solid (100 mg) by crystallization
28 from hot DCM. Mp 177-178 °C. IR (ATR) ν : 672, 747, 935, 964, 995, 1093, 1116, 1152,
29 1191, 1212, 1248, 1416, 1465, 1550, 1599, 1664, 2930, 3302 cm⁻¹. ¹H-NMR (400 MHz,
30 CDCl₃), δ : 1.70 [dm, $J = 12.4$ Hz, 2 H, 4'(10')-H_a], 1.76-1.94 [complex signal, 4 H, 6'-H₂,
31 8'(9')-H_a], 2.01 [dm, $J = 12.4$ Hz, 2 H, 4'(10')-H_b], 2.18 [dm, $J = 12.4$ Hz, 2 H, 8'(9')-H_b],
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

1
2
3 2.32 [m, 2 H, 5'(7')-H], 4.41 (m, 1 H, 3'-H), 5.36 (broad s, 1 H, 1'-NH), 6.87 (m, 1 H, 4-H),
4
5 7.29-7.35 (complex signal, 2 H, 2-H, 6-H), 8.47 (broad s, 1 H, 1-NH). ¹³C-NMR (100.5 MHz,
6
7 CDCl₃) δ: 27.9 [CH, C5'(7')], 34.4 (CH₂, C6'), 34.7 [CH₂, C4'(10')], 40.5 [CH₂, C8'(9')],
8
9 71.5 (C, C3'), 81.2 (C, C1'), 110.0 (CH, C6), 115.1 (CH, C4), 117.2 (CH, C2), 120.3 (q, J =
10
11 258.3 Hz, C, CF₃), 135.1 (C, C3), 141.0 (C, C1), 149.8 (m, C, C5), 154.6 (C, CO). HRMS:
12
13 Calculated for [C₁₇H₁₈ClF₃N₂O₃+H]⁺: 391.1031. Found: 391.1038.
14
15

16
17 **1-(-2-Oxaadamantan-1-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea, 31.** To a
18
19 solution of the commercial 4-chloro-3-(trifluoromethyl)phenyl isocyanate (191 mg, 0.84
20
21 mmol) in DCM were added 2-oxaadamantan-1-amine hydrochloride (145 mg, 0.76 mmol)
22
23 and triethylamine (0.21 mL, 1.52 mmol). The reaction mixture was stirred at room
24
25 temperature overnight. The mixture was evaporated under vacuum to give a solid that was
26
27 then dissolved in EtOAc (20 mL) and washed with 2N HCl solution (10 mL). The organic
28
29 phase was dried over anh. Na₂SO₄ and filtered. Evaporation under vacuum of the organics
30
31 gave urea **31** as a white solid (238 mg, 83% yield). The analytical sample was obtained by
32
33 crystallization from hot EtOAc (127 mg). Mp 196 °C. IR (ATR) ν: 661, 721, 765, 785, 824,
34
35 835, 881, 930, 961, 987, 1028, 1093, 1114, 1134, 1170, 1191, 1209, 1253, 1289, 1297, 1323,
36
37 1374, 1416, 1485, 1550, 1586, 1607, 1671, 2118, 2144, 2217, 2351, 2847, 2925, 3054, 3100,
38
39 3235, 3286 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ: 1.69 [dm, J = 12.6 Hz, 2 H, 4'(10')-H_a],
40
41 1.77-1.93 [complex signal, 4 H, 6'-H₂, 8'(9')-H_a], 2.01 [dm, J = 12.6 Hz, 2 H, 4'(10')-H_b],
42
43 2.19 [m, J = 12.0 Hz, 2 H, 8'(9')-H_b], 2.32 [m, 2 H, 5'(7')-H], 4.41 (m, 1 H, 3'-H), 5.42
44
45 (broad s, 1H, 1'-NH), 7.37 (d, J = 8.6 Hz, 1 H, 5-H), 7.56 (dd, J = 8.6 Hz, J' = 2.6 Hz, 6-H),
46
47 7.71 (d, 1 H, J = 2.6 Hz, 2-H), 8.4 (broad s, 1 H, 1-NH). ¹³C-NMR (100.5 MHz, CDCl₃) δ:
48
49 27.9 [CH, C5'(7')], 34.4 (CH₂, C6'), 34.7 [CH₂, C4'(10')], 40.4 [CH₂, C8'(9')], 71.4 (CH,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 C3'), 81.2 (C, C1'), 118.2 (q, $^3J_{C-F} = 6.0$ Hz, CH, C2), 122.7 (q, $^1J_{C-F} = 273$ Hz, C, CF₃),
4
5 123.2 (CH, C6), 125.1 (C, C4), 128.5 (q, $^2J_{C-F} = 31.3$ Hz, C, C3), 131.8 (CH, C5), 137.7 (C,
6
7 C1), 154.8 (C, CO). HRMS: Calculated for [C₁₇H₁₈ClF₃N₂O₂+H]⁺: 375.1082. Found:
8
9 375.1090.
10

11
12 **1-(-2-Oxaadamantan-1-yl)-3-(3-(pentafluoro- λ^6 -sulfanyl)phenyl)urea, 32.** A solution of
13
14 3-(pentafluoro- λ^6 -sulfanyl)aniline (185 mg, 0.84 mmol) in toluene (3.6 mL) was treated with
15
16 triphosgene (125 mg, 0.42 mmol). Immediately, triethylamine (0.12 mL, 0.84 mmol) was
17
18 added and the reaction mixture was stirred at 70 °C for 2 hours. Afterwards, pentane (0.5
19
20 mL) was added and a white precipitate was formed. The mixture was filtered and pentane
21
22 was evaporated under vacuum at room temperature to give the isocyanate in toluene solution
23
24 that was used in the next step without further purification. To a solution of the 3-(pentafluoro-
25
26 λ^6 -sulfanyl)phenyl isocyanate from the previous step were added DCM (5 mL), 2-
27
28 oxaadamantan-1-amine hydrochloride (145 mg, 0.76 mmol) and triethylamine (0.21 mL,
29
30 1.52 mmol). The suspension was stirred at room temperature overnight. The mixture was
31
32 evaporated under vacuum to give a solid that was then dissolved in DCM (20 mL) and washed
33
34 with aqueous 2N HCl solution. The organic phase was dried over anh. Na₂SO₄ and filtered.
35
36 Evaporation under vacuum of the organics gave urea **32** (237 mg, 71% overall yield) as a
37
38 pale yellow solid. The analytical sample was obtained by crystallization from hot EtOAc as
39
40 a white solid (75 mg). Mp 203 °C. IR (ATR) ν : 649, 685, 734, 785, 824, 835, 863, 946, 959,
41
42 990, 1093, 1114, 1199, 1250, 1256, 1292, 1318, 1369, 1431, 1478, 1537, 1591, 1671, 1966,
43
44 2041, 2930, 3080, 3224, 3286 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ : 1.69 [dm, $J = 11.8$ Hz,
45
46 2 H, 4'(10')-H_a], 1.78-1.94 [complex signal, 4 H, 6'-H₂, 8'(9')-H_a], 2.01 [dm, $J = 11.8$ Hz, 2
47
48 H, 4'(10')-H_b], 2.21 [m, $J = 12.4$ Hz, 2 H, 8'(9')-H_b], 2.32 [m, 2 H, 5'(7')-H], 4.42 (m, 1 H,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 3'-H), 5.43 (broad s, 1H, 1'-NH), 7.35 (d, $J = 8.2$ Hz, 1 H, 6-H), 7.39 (dq, $J = 8.2$ Hz, $J' =$
4
5 1.2 Hz, 1 H, 5-H), 7.52 (d, $J = 8.2$ Hz, 1 H, 4-H), 7.86 (t, $J = 2.0$ Hz, 1 H, 2-H), 8.50 (broad
6
7 s, 1 H, 1-NH). ^{13}C -NMR (100.5 MHz, CDCl_3) δ : 27.9 [CH, C5'(7')], 34.5 (CH_2 , C6'), 34.7
8
9 [CH₂, C4'(10')], 40.4 [CH₂, C8'(C9')], 71.4 (CH, C3'), 81.2 (C, C1'), 116.9 (m, CH, C2),
10
11 120.1 (m, CH, C4), 122.3 (CH, C6), 128.9 (CH, C5), 139.2 (C, C1), 154.3 (C, C3), 154.9 (C,
12
13 CO). HRMS: Calculated for $[\text{C}_{16}\text{H}_{19}\text{F}_5\text{N}_2\text{O}_2\text{S}+\text{H}]^+$: 399.1160. Found: 399.1172.

14
15
16
17 **Determination of IC₅₀ sEH inhibitors in human, murine and rat purified sEH.** IC₅₀ is
18
19 the concentration of a compound that reduces the sEH activity by 50%. The IC₅₀ values
20
21 reported herein were determined using a fluorescent based assay (CMNPC as substrate).⁵³
22
23 The fluorescent assay was used with purified recombinant human, mouse or rat sEH proteins.
24
25 The enzymes were incubated at 30 °C with the inhibitors ($[\text{I}]_{\text{final}} = 0.4 - 100,000$ nM) for 5
26
27 min in 100 mM sodium phosphate buffer (200 μL , pH 7.4) containing 0.1 mg/mL of BSA
28
29 and 1% of DMSO. The substrate (CMNPC) was then added ($[\text{S}]_{\text{final}} = 5$ μM). Activity was
30
31 assessed by measuring the appearance of the fluorescent 6-methoxynaphthaldehyde product
32
33 ($\lambda_{\text{ex}} = 330$ nm, $\lambda_{\text{em}} = 465$ nm) every 30 seconds for 10 min at 30 °C on a PspectraMax M2
34
35 (molecular devices). Results were obtained by regression analysis from a linear region of the
36
37 curve.
38
39
40
41
42

43 ***In silico* study. Molecular Dynamics Simulations Details.** The parameters for AR9273, **22**,
44
45 and **26**, for the MD simulations were generated within the ANTECHAMBER module of
46
47 AMBER 18⁵⁴ using the general AMBER force field (GAFF),⁵⁵ with partial charges set to fit
48
49 the electrostatic potential generated at the HF/6-31G(d) level by the RESP model.⁵⁶ The
50
51 charges were calculated according to the Merz-Singh-Kollman scheme⁵⁷⁻⁵⁸ using Gaussian
52
53
54 09.⁵⁹
55
56
57
58
59
60

1
2
3 MD simulations of sEH were carried out using PDB 5ALZ (crystallized with AR9273)³⁸ as
4 a reference. For the MD simulations in the *apo* state the AR9273 was removed from the
5 active site. The oxaadamantyl derivatives corresponding to compounds **22** and **26** were
6 manually prepared using AR9273 structure as starting point. From these coordinates,
7 conventional MD simulations were used to explore the conformational plasticity of sEH in
8 the *apo* state and in the presence of AR9273, **22**, and **26** bound in the active site. Amino acid
9 protonation states were predicted using the H⁺⁺ server (<http://biophysics.cs.vt.edu/H++>).
10 The MD simulations have been carried with the following protonation of histidine residues:
11 HIE146, HIE239, HIP251, HID265, HIP334, HIE420, HIE506, HIE513, HIE518, and
12 HIP524.
13

14 Each system was immersed in a pre-equilibrated truncated octahedral box of water molecules
15 with an internal offset distance of 10 Å. All systems were neutralized with explicit
16 counterions (Na⁺ or Cl⁻). A two-stage geometry optimization approach was performed. First,
17 a short minimization of the positions of water molecules with positional restraints on solute
18 by a harmonic potential with a force constant of 500 kcal mol⁻¹ Å⁻² was done. The second
19 stage was an unrestrained minimization of all the atoms in the simulation cell. Then, the
20 systems were gently heated in six 50 ps steps, increasing the temperature by 50 K each step
21 (0-300 K) under constant-volume, periodic-boundary conditions and the particle-mesh Ewald
22 approach⁶⁰ to introduce long-range electrostatic effects. For these steps, a 10 Å cut-off was
23 applied to Lennard-Jones and electrostatic interactions. Bonds involving hydrogen were
24 constrained with the SHAKE algorithm.⁶¹ Harmonic restraints of 10 kcal mol⁻¹ were applied
25 to the solute, and the Langevin equilibration scheme was used to control and equalize the
26 temperature.⁶² The time step was kept at 2 fs during the heating stages, allowing potential
27 inhomogeneities to self-adjust. Each system was then equilibrated for 2 ns with a 2 fs
28

1
2
3 timestep at a constant pressure of 1 atm. Finally, conventional MD trajectories at constant
4
5 volume and temperature (300 K) were collected. In total, three replicas of 250 ns MD
6
7 simulations for sEH in the *apo* state and in the presence of AR9273, **22**, and **26** were run,
8
9 gathering a total of 3 μ s of MD simulation time. The relative binding free energy was
10
11 calculated for compounds **22** and **22-CH₂** using the TI method.⁶³ The NPT ensemble was
12
13 used for equilibrating the system and the production runs for the TI calculations using a
14
15 timestep of 1fs and the same simulation protocols as described above. The schedule of
16
17 lambda windows chosen consists of 11 λ values: 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,
18
19 1.0. The initial equilibrations of 4 ns were performed using a λ of 0.5 and this configuration
20
21 was used as starting point for neighbouring lambda windows. The TI runs were run for 4 ns
22
23 and frames were collected every 0.5 ps for post-analysis and relative binding free energy
24
25 calculations.
26
27
28
29
30

31
32 The octanol/water partition coefficient, LogP, of compound **22** and **22-CH₂** was calculated
33
34 from the solvation free energy differences using the M06-2X functional⁶⁴ with SMD implicit
35
36 solvation⁶⁵ and the def2-SVP basis set⁶⁶ as described by Guan *et al.*⁴² Solvated geometry
37
38 optimizations were performed using M06-2X/def2-SVP and SMD using water and 1-octanol
39
40 as solvents. To calculate the LogP, the free energies obtained at 298.15 K using octanol and
41
42 water as solvents were employed to compute the standard free energy associated with the
43
44 transfer of the solute from the water to octanol phases as:
45
46
47

$$\log P = \frac{\Delta G_{\text{solvation}(\text{water})} - \Delta G_{\text{solvation}(\text{octanol})}}{2.303RT} \quad (1)$$

48
49
50
51
52 **Solubility.** The stock solutions (10⁻² M) of assayed compounds were diluted to decreased
53
54 molarity, from 300 μ M to 0.1 μ M, in 384 well transparent plate (Greiner 781801) with 1%
55
56
57

1
2
3 DMSO:99% PBS buffer. Then, they were incubated at 37 °C and the light scattering was
4
5 measured after 2 hours in a NEPHELOstar Plus (BMG LABTECH). The results were
6
7 adjusted to a segmented regression to obtain the maximum concentration in which
8
9 compounds are soluble.
10

11 **Permeability.** The Caco-2 cells were cultured to confluency, trypsinized and seeded onto a
12
13 96-filter transwell insert (Corning) at a density of ~10,000 cells/well in DMEM cell culture
14
15 medium supplemented with 10% Foetal Bovine Serum, 2 mM L-Glutamine and 1%
16
17 penicillin/streptomycin. Confluent Caco-2 cells were subcultured at passages 58-62 and
18
19 grown in a humidified atmosphere of 5% CO₂ at 37 °C. Following an overnight attachment
20
21 period (24 h after seeding), the cell medium was replaced with fresh medium in both the
22
23 apical and basolateral compartments every other day. The cell monolayers were used for
24
25 transport studies 21 days post seeding. The monolayer integrity was checked by measuring
26
27 the transepithelial electrical resistance (TEER) obtaining values $\geq 500 \Omega/\text{cm}^2$. On the day of
28
29 the study, after the TEER measurement, the medium was removed and the cells were washed
30
31 twice with pre-warmed (37 °C) Hank's Balanced Salt Solution (HBSS) buffer to remove
32
33 traces of medium. Stock solutions were made in dimethyl sulfoxide (DMSO), and further
34
35 diluted in HBSS (final DMSO concentration 1%). Each compound and reference compounds
36
37 (Colchicine, E3S) were all tested at a final concentration of 10 μM . For A \rightarrow B directional
38
39 transport, the donor working solution was added to the apical (A) compartment and the
40
41 transport media as receiver working solution was added to the basolateral (B) compartment.
42
43 For B \rightarrow A directional transport, the donor working was added to the basolateral (B)
44
45 compartment and transport media as receiver working solution was added to the apical (A)
46
47 compartment. The cells were incubated at 37 °C for 2 hours with gentle stirring.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 At the end of the incubation, samples were taken from both donor and receiver compartments
4 and transferred into 384-well plates and analyzed by UPLC-MS/MS. The detection was
5 performed using an ACQUITY UPLC /Xevo TQD System. After the assay, Lucifer yellow
6 was used to further validate the cell monolayer integrity, cells were incubated with LY 10
7 μM in HBSS for 1 hour at 37 °C, obtaining permeability (P_{app}) values for LY of $\leq 10 \text{ nm/s}$
8 confirming the well-established Caco-2 monolayer.
9

10
11 **Cytotoxicity in PBMCs cells + 1.5% PHA (Phytohaemagglutinin).** Cytotoxic effects of
12 assayed compounds were tested using peripheral blood mononuclear cells isolated following
13 the regular density gradient centrifugation procedure with Ficol. Cells were plated in 96-well
14 black microplates at 270.000 cells/well density with RPMI medium (containing 10% FBS,
15 1% NEAA, 1% P/S and 1.5% PHA). The tested compounds were solubilized in 100% DMSO
16 at a concentration curve way and then diluted with cell culture medium containing 2%
17 DMSO. The final concentrations of the test compounds (0.2% DMSO) ranged from 0-20 μM
18 in a final volume of 150 μL . Microplates were maintained at 37 °C (5% CO_2 , 95% humidity)
19 for 3 days. Following this 72 hour exposure to test compounds, cell viability in each well was
20 determined by measuring the concentration of cellular adenosine triphosphate (ATP) using
21 the ATP1Step Kit as described by the manufacturer (Perkin-Elmer). In a typical procedure,
22 80 μL of cell reagent was added to all wells of each test plate followed by incubation for 10
23 min at room temperature on an orbital shaker. ATP concentration was determined by reading
24 chemical luminescence using the Envision plate reader (PerkinElmer). The percentage of
25 viable cells relative to the non-drug treated controls was determined for each well and LC_{50}
26 values were calculated as concentrations projected to kill 50% of the cells following a 72
27 hours exposure.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Cytotoxicity in THLE-2 cells.** Cytotoxic effects of assayed compounds were tested using
4 the immortalized human liver cell line THLE-2 (ATCC CRL-2706). Cells were cultured in
5 BEGM medium (Clonetics #CC-4175) containing all the supplements kit except additional
6 EGF and G418. Medium was completed by adding 0.7 $\mu\text{g/mL}$ phosphoethanolamine, 0.5
7 ng/mL epidermal growth factor, antibiotics (penicillin and streptomycin) and 10% fetal
8 bovine serum (FBS). Cells were plated in 96-well black microplates at 10,000 cells/well
9 density and were incubated at 37 $^{\circ}\text{C}$ (5% CO_2 , 95% humidity) for 24 hours to allow the cells
10 to adhere and form a monolayer. Test compounds were solubilized in 100% DMSO at a
11 concentration curve way and then diluted with cell culture medium containing 10% DMSO.
12 The final concentrations of the test compounds (1% DMSO) ranged from 0-100 μM in a final
13 volume of 200 μL . Microplates were maintained at 37 $^{\circ}\text{C}$ (5% CO_2 , 95% humidity) during 3
14 days. Following this 72 h exposure to test compounds, cell viability in each well was
15 determined by measuring the concentration of cellular adenosine triphosphate (ATP) using
16 the ATP1Step Kit as described by the manufacturer (Perkin-Elmer). In a typical procedure,
17 50 μL of cell reagent was added to all wells of each test plate followed by incubation for 10
18 min at room temperature on an orbital shaker. ATP concentration was determined by reading
19 chemical luminescence using the Envision plate reader (PerkinElmer). The percentage of
20 viable cells relative to the non-drug treated controls was determined for each well and LC_{50}
21 values were calculated as concentrations projected to kill 50% of the cells following a 72
22 hours exposure.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Parallel Artificial Membrane Permeation Assays - Blood-Brain Barrier (PAMPA-**
49 **BBB).** To evaluate the brain penetration of the different compounds, a parallel artificial
50 membrane permeation assay for blood-brain barrier was used, following the method
51 described by Di *et al.*⁴³ The *in vitro* permeability (P_e) of fourteen commercial drugs through
52
53
54
55
56
57

lipid extract of porcine brain membrane together with the test compounds were determined. Commercial drugs and assayed compounds were tested using a mixture of PBS:EtOH (70:30). Assay validation was made by comparing the experimental permeability with the reported values of the commercial drugs by bibliography and lineal correlation between experimental and reported permeability of the fourteen commercial drugs using the parallel artificial membrane permeation assay was evaluated ($y = 1.5219x - 0.9129$; $R^2 = 0.9387$). From this equation, and taking into account the limits established by Di *et al.*⁴³ for BBB permeation, we established the ranges of permeability as compounds of high BBB permeation (CNS+): $Pe (10^{-6} \text{ cm}^{\text{s}^{-1}}) > 5.149$; compounds of low BBB permeation (CNS-): $Pe (10^{-6} \text{ cm}^{\text{s}^{-1}}) < 2.131$ and compounds of uncertain BBB permeation (CNS+/-): $5.149 > Pe (10^{-6} \text{ cm}^{\text{s}^{-1}}) > 2.131$.

Cytochrome P450 inhibition assay. The objective of this study was to screen the inhibition potential of the compounds using recombinant human cytochrome P450 enzymes CYP3A4 (BFC and DBF substrates) and probe substrates with fluorescent detection. Incubations were conducted in a 200 μL volume in 96 well microtiter plates (COSTAR 3915). Adding the mixture buffer-cofactor (KH_2PO_4 buffer, 1.3 mM NADP, 3.3 mM MgCl_2 , 0.4 U/mL Glucose-6-phosphate Dehydrogenase), Control supersomes the standard inhibitor Ketoconazole (Sigma K1003) and pre-diluted compounds. The plate was then pre-incubated at 37 $^\circ\text{C}$ for 5 min in 100 μL volume and reaction initiated by the addition of pre-warmed enzyme/substrate (E/S) mix. The E/S mix contained buffer (KH_2PO_4), enzyme (CYP), substrate 7-benzyloxytrifluoromethyl coumarin (7-BFC) and Dibenzylfluorescein (DBF) in a reaction volume of 200 μL . Reactions were terminated after various times depending on the substrate by addition of STOP solution (ACN/TrisHCl 0.5M 80:20 (BFC) or 2N NaOH for CYP3A4

(DBF). Fluorescence per well was measured using a fluorescence plate reader (Tecan M1000 pro) and percentage of inhibition was calculated.

Microsomal stability. The human microsomes employed were purchased from Tebu-Xenotech. The compound was incubated at 37 °C with the microsomes in a 50 mM phosphate buffer (pH = 7.4) containing 3 mM MgCl₂, 1 mM NADP, 10 mM glucose-6-phosphate and 1 U/mL glucose-6-phosphate-dehydrogenase. Samples (75 μL) were taken from each well at 0, 10, 20, 40 and 60 min and transferred to a plate containing 75 μL acetonitrile, and 30 μL of 0.5% formic acid in water were added for improving the chromatographic conditions. The plate was centrifuged (46000 g, 30 min) and supernatants were taken and analyzed in a UPLC-MS/MS (Xevo-TQD, Waters) by employing a BEH C18 column and an isocratic gradient of 0.1% formic acid in H₂O : 0.1% formic acid acetonitrile (60:40). The metabolic stability of the compounds was calculated from the logarithm of the remaining compounds at each of the time points studied.

Inhibition of human lipoxygenase-5 (*h*LOX-5). AA and 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA) were obtained from Sigma. Human recombinant LOX-5 was purchased from Cayman Chemical. For the determination of *h*LOX-5 activity, the method described by Pufahl et al. was followed.⁶⁷ The assay solution consisted of 50 mM Tris (pH 7.5), 2 mM EDTA, 2 mM CaCl₂, 3 μM AA, 10 μM ATP, 10 μM H₂DCFDA and 100 mU/well *h*LOX-5. For the enzyme inhibition studies the compounds to be tested were added to the assay solution prior to AA and ATP and were preincubated for a period of 10 min at room temperature, after which AA and ATP were added. The enzymatic reaction was carried out for 20 min and terminated by the addition of 40 μL of acetonitrile. The fluorescence measurement, 485 nm excitation and 520 nm emission, was performed on a FLUOstar

1
2
3 OPTIMA (BMG LABTECH, Offenburg, Germany.). The IC_{50} is defined as the concentration
4
5 of compound that inhibits enzymatic activity by 50% over the untreated enzyme control.
6

7 ***In vitro* proof of concept.** Rat pancreatic AR42J acinar cells were purchased from ATCC
8
9 and cultured in RPMI-1680 (Gibco) supplemented with 10% fetal bovine serum, 2 mM
10
11 glutamine, 100 μ g/mL streptomycin and 100 units/ml penicillin at 37 °C in a humidified
12
13 atmosphere containing 5% CO_2 . Medium was changed every 48 hours. AR42J cells plated
14
15 into 6-well plate and incubated for 24-48 hours, (one or the other) were pre-treated with sEH
16
17 inhibitors for 1 hour and, later, treated with sEH inhibitors plus cerulein 10 nM (treated
18
19 group) for 8 hours. The same volume of saline serum (0.9% NaCl) was added to the control
20
21 cultures (control group).
22
23
24
25

26 **Pharmacokinetic study.** Mice used in this study were Hsd:ICR (CD-1) (females, 6-7 weeks
27
28 old supplied by ENVIGO). Animals were housed under sterile conditions at a constant
29
30 temperature of 20-22 °C and relative humidity (45-65%) under daily cycles of light/darkness
31
32 (12 hours). Manipulation was performed in laminar flow hood and sterilized water and food
33
34 were available ad libitum. The procedure involving experimental animals was approved by
35
36 the “Ethical Committee of Animal Experimentation” of the animal facility plate at Science
37
38 Park of Barcelona (Platform of Applied Research in Animal Laboratory). Once approved by
39
40 the Institutional ethical committee, this procedure was additionally approved by the ethical
41
42 committee of the Catalonian authorities according to the Catalonian and Spanish regulatory
43
44 laws and guidelines governing experimental animal care. Along the procedures using
45
46 experimental animals, we also established a continuous supervision and control of the
47
48 animals to monitor their degree of suffering and if needed to sacrifice them according to the
49
50 defined end point criteria described by the United Kingdom Coordinating Committee of
51
52
53
54
55
56
57
58
59
60

1
2
3 Cancer Research (UKCCCR), by the Canadian Council on Animal Care (1998), by the
4
5 Institute for Laboratory Research Journal (2000), by the Conference 22-25 November 1998
6
7 Zeist (The Netherlands) and by the Guidelines for the welfare and use of animals in cancer
8
9 research (2010). The euthanasia method applied was by CO₂ saturated atmosphere.
10
11 Formulations were prepared the day of the study. Vehicle was saline solution + 5% DMSO.
12
13 21 mice were administered intravenously (iv) with a single dose of 1 mg/kg of compound **22**.
14
15 The volume of administration was 5 mL/kg. 21 mice were administered intraperitoneally (ip)
16
17 with a single dose of 1 mg/kg of compound **22**. The volume of administration was 10 mL/kg.
18
19 Animals were weighed before each administration to adjust the required volume. Compound
20
21 **22** was administered by ip or iv and animals were killed under a CO₂ saturated atmosphere
22
23 to obtain blood samples. Blood samples were collected at different times post administration:
24
25 0 h, 10', 30', 1 h, 2 h, 4 h, 6 h, and 24 h. Samples were taken by cardiac puncture at different
26
27 times post administration (3 animals per time). Blood was collected on recipients containing
28
29 5 μL of EDTA 0.5 M. Blood was centrifuged at 5000 rpm for 10 min. 100 μL of each plasma
30
31 sample (BK, calibration standards and study samples) were mixed with 300 μL of methanol
32
33 and 60 μL of ISTD in a Sirocco plate. Plate was centrifuged at 2000 rpm for 10 min. After
34
35 that, sample were dried at 40 °C under N₂ streaming and reconstituted with 110 μL of
36
37 MeOH:H₂O 0.1% HCOOH 1:1. Concentrations of compound **22** were analyzed by UPLC-
38
39 MS.

40
41
42 **Maximum tolerated dose study.** Mice used in this study were Hsd:ICR (CD-1) females, 6-7
43
44 weeks old supplied by ENVIGO. Animals were housed under sterile conditions at a constant
45
46 temperature of 20-22 °C and relative humidity (45-65%) under daily cycles of light/darkness
47
48 (12 hours). Manipulation was performed in laminar flow hood and sterilized water and food
49
50 were available ad libitum. The procedure involving experimental animals was approved by
51
52
53
54
55
56
57
58
59
60

1
2
3 the “Ethical Committee of Animal Experimentation” of the animal facility plate at Science
4 Park of Barcelona (Platform of Applied Research in Animal Laboratory). Once approved by
5 the Institutional ethical committee, this procedure was additionally approved by the ethical
6 committee of the Catalonian authorities according to the Catalonian and Spanish regulatory
7 laws and guidelines governing experimental animal care. Along the procedures using
8 experimental animals, we also establish a continuous supervision and control of the animals
9 to monitor their degree of suffering and if needed to sacrifice them according to the defined
10 end point criteria described by the United Kingdom Coordinating Committee of Cancer
11 Research (UKCCCR), by the Canadian Council on Animal Care (1998), by the Institute for
12 Laboratory Research Journal (2000), by the Conference 22-25 November 1998 Zeist (The
13 Netherlands) and by the Guidelines for the welfare and use of animals in cancer research
14 (2010). The euthanasia method applied was by CO₂ saturated atmosphere. Animal weight
15 was monitored daily. The criteria for end point before the end of the assay was that the mean
16 of weight loss from any group reaches 15% or more; also, any individual mouse with a loss
17 of 20% should be sacrificed. Body weight was monitored daily previous to administration.
18 The body weight loss was calculated according to the formula: $((\text{Weight} - \text{weight start}) /$
19 $\text{weight start}) \times 100$. Compound **22** was administered by ip for 5 consecutively days and, after
20 then, animals’ weight was monitored for 5 days more. Then, animals were killed under a CO₂
21 saturated atmosphere to obtain samples. Five groups were performed taking into account the
22 administered dose. G1: Control vehicle, 5 days (n = 6). G2: Compound **22** at 80 mg/kg, 5
23 days (n = 6). G3: Compound **22** at 20 mg/kg, 5 days (n = 6). G4: Compound **22** at 10 mg/kg,
24 5 days (n = 6). G5: Compound at 5 mg/kg, 5 days (n = 6).

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54 ***In vivo* efficacy study.** Compound **22** was administered before (pre) and after (post)
55 induction of acute pancreatitis with cerulein (50 µg/kg body weight, 12 times at 1-hour
56
57
58
59
60

1
2
3 intervals) in 8- to 10-week-old male mice (C57BL/6J), as previously described.³⁴ In the post-
4
5 induction studies, **22** (3 and 30 mg/kg) was administered in one injection 24 hours after
6
7 induction of AP. In the pre-induction studies, sEH inhibitors were administered at the same
8
9 dose for 5 consecutive days 2-times/day before induction of AP. Animals were sacrificed 24
10
11 hours after the end of the treatment and blood and tissues were collected and flash-frozen at
12
13 -80 °C. Mice were treated in accordance with the European Community Council Directive
14
15 86/609/EEC and the procedures established by the *Department d'Agricultura, Ramaderia i*
16
17 *Pesca of the Generalitat de Catalunya*.
18
19

20
21 **Histologic analyses.** A portion of the pancreas was fixed in 4% paraformaldehyde and
22
23 sections were stained with H&E to observe morphologic changes. Histologic analysis was
24
25 performed as previously described.³⁴
26
27

28 **RNA preparation and quantitative RT-PCR.** RNA was extracted from AR42J cells and
29
30 pancreatic tissue using Trisure reagent (TRIsure Bio-38032, Bio-Rad) according to the
31
32 manufacturer's recommended protocol. Normally, 1 µg of total RNA was reverse-transcribed
33
34 into cDNA and the relative levels of specific mRNAs were assessed by real-time PCR with
35
36 MiniOpticon Real-Time PCR system (Bio-Rad). The primer sequences used are shown in
37
38 Supporting Information.
39
40
41
42
43

44 ASSOCIATED CONTENT

45 Supporting Information

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ^1H and ^{13}C NMR spectra and elemental analysis data of the new compounds,
4
5
6
7 inhibition of *h*LOX-5 and *h*COX-2 and Pharmacokinetic data of compound **22** (PDF).
8
9
10 Molecular formula string and data (CSV). This material is available free of charge via
11
12
13
14 the Internet at <http://pubs.acs.org>.
15
16
17

18 AUTHOR INFORMATION

21 Corresponding author

22
23
24
25
26
27 *E-mail: svazquez@ub.edu Phone: +34 934024533
28
29
30

31 ORCID

32
33
34
35 Santiago Vázquez: 0000-0002-9296-6026
36
37
38
39

40 Notes

41
42
43
44 S.C., E.V., R.L., M.V.-C. and S.V. are inventors of the Universitat de Barcelona
45
46
47 patent application on sEH inhibitors WO2017/017048. C.M. and B.D.H. are inventors
48
49
50
51 of the University of California patents on sEH inhibitors licensed to EicOsis. None of
52
53
54
55 the other authors has any disclosures to declare.
56
57
58
59
60

Author Contributions

S.C., E.P. and E.V. synthesized and chemically characterized the compounds. J. P. and M.V-C. designed and carried out the AR42J cell line and the *in vivo* experiments. C. M. and B.D.H. performed the determination of the IC₅₀ in human, murine and rat sEH. F.F. and S.O. performed MD calculations. M.I.L and J.M.B carried out DMPK studies. E.S., J.O. and A.P.-L. performed cytotoxicity studies. B.P. carried out the PAMPA studies. C.P. and M.I.R.-F. performed the *h*LOX-5 studies. S.C., E.P., J.P., R.L., C.M., B.D.H., M.V-C. and S.V. analyzed the data. R.L. and S.V. conceived the idea. S.C. and S.V. wrote the manuscript with feedback from all the authors. All authors have given approval to the final version of the manuscript.

ACKNOWLEDGEMENTS

This work was funded by the Spanish *Ministerio de Economía, Industria y Competitividad* (Grants SAF2017-82771-R to S.V., SAF2015-64146-R and RTI2018-093999-B-I00 to M. V.-C., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S. O. and RTI2018-101032-J-I00 to F. F.), the *CaixaImpulse 2015*

1
2
3 *Programme*, the *Spain EIT Health* (Proof of concept 2016), the European Regional
4
5
6
7 Development Fund (ERDF), the *Xunta de Galicia* (GRC2014/011 and ED431C2018-
8
9
10 21), the *Fundació Bosch i Gimpera, Universitat de Barcelona* (F2I grant), the
11
12
13 *Generalitat de Catalunya* (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the
14
15
16 *Fundación Fuentes Dutor*, the *European Research Council* (ERC-2015- StG-
17
18 679001-NetMoDEzyme to S.O.), and the *European Community* (MSCA-IF-2014-EF-
19
20 661160-MetAccembly to F.F.). S.C. and E.P. acknowledge PhD fellowships from the
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Universitat de Barcelona (APIF grants). E.V. and R.L. thank the Institute of
Biomedicine of the University of Barcelona (IBUB) and the Spanish *Ministerio de
Educación, Cultura y Deporte* (FPU grant), respectively, for PhD grants. Partial
support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS
Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01
DK103616. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health. We thank
Daniel Closa (IIBB-CSIC, Barcelona, Spain) for advice regarding the hystologic
analyses.

ABBREVIATIONS USED

AP, Acute Pancreatitis; ATF3, Activating Transcription Factor 3; ATR, Attenuated Total Reflectance; BEGM, Bronchial Epithelial Growth Medium; BEH, Ethylene Bridged Hybrid; BFC, Benzyloxytrifluoromethylcoumarin; CER, cerulein; CHOP, C/EBP homologous protein; DBF, Dibenzylfluorescein; DiHETrE, Dihydroxyeicosatrienoic Acids; DIPEA, Diisopropylethyl Amine; E/S, Enzyme/Substrate; EDCI·HCl, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; EETs, Epoxyeicosatrienoic Acids; ER, Endoplasmic Reticulum; ERCP, Endoscopic Retrograde Cholangiopancreatography; EtOAc, Ethyl Acetate; FBS, Fetal Bovine Serum; Fs, Femtosecond; G418, Geneticin; H&E, Hematoxylin and Eosin; HOBt, Hydroxybenzotriazole; hsEH, human soluble Epoxide Hydrolase; IL, Interleukin; KO, Knockout; LC₅₀, Concentration of the compound that is lethal for 50% of exposed population; LOX, Lipoxygenases; MCP-1, Monocyte Chemoattractant Protein 1; msEH, murine soluble Epoxide Hydrolase; NCI, non-covalent interactions; ND, Not Done; NEAA, Non-Essential Amino Acid; P/S,

1
2
3 Penicillin/Streptomycin solution; PBMC, Peripheral Blood Mononuclear Cells; Pe,
4
5
6 Permeability; PHA, Phytohaemagglutinin; PHOME, (3-Phenyl-oxiranyl)-acetic acid
7
8
9
10 cyano-(6-methoxy-naphthalen-2-yl)-methyl ester; PMSF, Phenylmethylsulfonyl
11
12
13 fluoride; RHS, Right-Hand Side; RPMI, Roswell Park Memorial Institute; sEH,
14
15
16 soluble Epoxide Hydrolase; THLE-2, Transformed Human Liver Epithelial-2 cell line;
17
18
19
20
21 TI, Thermodynamic Integration; TRB3, Tribbles homolog 3.
22
23
24

25 REFERENCES

- 26
27
28 1. The Role of Bioactive Lipids in Cancer, Inflammation and Related Diseases in
29
30
31
32 *Advances in Experimental Medicine and Biology*, K. V. Honn, D. C. Zeldin, Eds.; Vol
33
34
35 1161, Springer, Cham, https://doi.org/10.1007/978-3-030-21735-8_1.
36
37
38
39
40 2. Meirer, K.; Steinhilber, D.; Proschak, E. Inhibitors of the arachidonic acid cascade:
41
42
43 interfering with multiple pathways. *Basic Clin. Pharmacol. Toxicol.* **2014**, *114*, 83-91.
44
45
46
47
48 3. Kaspera, R.; Totah, R. A. Epoxyeicosatrienoic acids: formation, metabolism and
49
50
51 potential role in tissue physiology and pathophysiology. *Expert Opin. Drug Metab.*
52
53
54 *Toxicol.* **2009**, *5*, 757-771.
55
56
57
58
59
60

1
2
3
4 4. Fleming, I. Cytochrome P450-dependent eicosanoid production and crosstalk.
5
6

7 *Curr. Opin. Lipidol.* **2011**, *22*, 403-409.
8
9

10
11 5. Capdevila, J. H.; Falck, J. R. The arachidonic acid monooxygenase: from
12
13
14 biochemical curiosity to physiological/pathophysiological significance. *J. Lipid Res.*
15
16

17
18 **2018**, *59*, 2047-2062.
19
20

21
22 6. Morisseau, C.; Hammock, B. D. Impact of soluble epoxide hydrolase and
23
24
25 epoxyeicosanoids on human health. *Annu. Rev. Pharmacol. Toxicol.* **2013**, *53*, 37-
26
27

28
29 58.
30
31

32
33 7. Harris T. R.; Hammock, B. D. Soluble epoxide hydrolase: gene structure,
34
35
36
37 expression and deletion. *Gene* **2013**, *526*, 61-74.
38
39

40
41 8. Pillarisetti, S.; Khanna I. A multimodal disease modifying approach to treat
42
43
44 neuropathic pain – inhibition of soluble epoxide hydrolase (sEH). *Drug Discov. Today*
45
46

47
48 **2015**, *20*, 1382-1390.
49
50

51
52 9. Wagner K. M.; McReynolds, C. B.; Schmidt, W. K.; Hammock, B. D. Soluble
53
54
55

1
2
3 epoxide hydrolase as a therapeutic target for pain, inflammatory and
4
5
6
7 neurodegenerative diseases. *Pharmacol. Ther.* **2017**, *180*, 62-76.
8
9

10
11 10. Borhan, B.; Jones, A. D.; Pinot, F.; Grant, D. F.; Kurth, M. J.; Hammock, B. D.
12
13
14 Mechanism of soluble epoxide hydrolase. *J. Biol. Chem.* **1995**, *270*, 26923-26930.
15
16
17

18
19 11. Gómez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Structure of
20
21
22 human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis
23
24
25
26 in epoxide and phosphate ester hydrolysis. *Biochemistry* **2004**, *43*, 4716-4723.
27
28
29

30
31 12. Shen, H. C.; Hammock, B. D. Discovery of inhibitors of soluble epoxide hydrolase:
32
33
34 a target with multiple potential therapeutic indications. *J. Med. Chem.* **2012**, *55*,
35
36
37 1789-1808.
38
39
40

41
42 13. Anandan, S. K.; Webb, H. K.; Chen, D.; Wang, Y.-X.; Aavula, B. R.; Cases, S.;
43
44
45 Cheng, Y.; Do, Z. N.; Mehra, U.; Tran, V.; Vincelette, J.; Waszczuk, J.; White, K.;
46
47
48 Wong, K. R.; Zhang, L.-N.; Jones, P. D.; Hammock, B. D.; Patel, D. V.; Whitcomb,
49
50
51 R.; MacIntyre, D. E.; Sabry, J.; Gless, R. 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-
52
53
54
55
56 yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide
57
58
59
60

1
2
3 hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
4
5

6
7 *Bioorg. Med. Chem. Lett.* **2011**, *21*, 983-988.
8
9

10
11 14. Chen, D.; Whitcomb, R.; MacIntyre, E.; Tran, V.; N. Do, Z.; Sabry, J.; Patel, D.
12

13
14 V.; Anandan, S. K.; Gless, R.; Webb, H. K. Pharmacokinetics and
15

16
17 pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single-
18

19
20 and multiple-dose studies in healthy human subjects. *J. Clin. Pharmacol.* **2012**, *52*,
21

22
23
24
25 319-328.
26

27
28
29 15. Jones, P. D.; Tsai, H.-J.; Do, Z. N.; Morisseau, C.; Hammock, B. D. Synthesis
30

31
32 and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
33

34
35
36 *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5212-5216.
37
38

39
40 16. Hwang, S. H.; Tsai, H.-J.; Liu, J.-Y.; Morisseau, C.; Hammock, B. D. Orally
41

42
43 bioavailable potent soluble epoxide hydrolase inhibitors. *J. Med. Chem.* **2007**, *50*,
44

45
46
47 3825-3840.
48

49
50 17. Brown, J. R.; North, E. J.; Hurdle, J. G.; Morisseau, C.; Scarborough, J. S.; Sun,
51

52
53 D.; Korduláková, J.; Scherman, M. S.; Jones, V.; Grzegorzewicz, A.; Crew, R. M.;
54
55

1
2
3 Jackson, M.; McNeil, M. R.; Lee, R. E. The structure-activity relationship of urea
4
5
6 derivatives as anti-tuberculosis agents. *Bioorg. Med. Chem.* **2011**, *19*, 5585-5595.
7
8

9
10
11 18. Bhattachar, S. N.; Deschenes, L. A.; Wesley, J. A. Solubility: it's not just for
12
13
14 physical chemists. *Drug Discov. Today.* **2006**, *11*, 1012-1018.
15
16

17
18
19 19. Di, L.; Fish, P. V; Mano, T. Bridging solubility between drug discovery and
20
21
22 development. *Drug Discov. Today.* **2012**, *17*, 486-495.
23
24

25
26
27 20. Gagneux, A. R.; Meier, R. 1-Substituted 2-heteroadamantanes. *Tetrahedron Lett.*
28
29
30 **1969**, *10*, 1365-1368.
31
32

33
34
35 21. Duque, M. D.; Camps, P.; Profire, L.; Montaner, S.; Vázquez, S.; Sureda, F. X.;
36
37
38 Mallol, J.; López-Querol, M.; Naesens, L.; De Clercq, E.; Prathalingam, S. R.; Kelly,
39
40
41 J. M. Synthesis and pharmacological evaluation of (2-oxadamantan-1-yl)amines.
42
43
44
45 *Bioorg. Med. Chem.* **2009**, *17*, 3198-3206.
46
47

48
49
50 22. Onajole, O. K.; Coovadia, Y.; Kruger, H. G.; Maguire, G. E. M.; Pillay, M.;
51
52
53 Govender, T. Novel polycyclic 'cage'-1,2-diamines as potential anti-tuberculosis
54
55
56

1
2
3 agents. *Eur. J. Med. Chem.* **2012**, *54*, 1-9.
4
5

6
7
8 23. Leiva, R.; Gazzarrini, S.; Esplugas, R.; Moroni, A.; Naesens, L.; Sureda, F. X.;
9
10 Vázquez, S. Ritter reaction-mediated syntheses of 2-oxaadamantan-5-amine, a
11
12 novel amantadine analog. *Tetrahedron Lett.* **2015**, *56*, 1272-1275.
13
14
15
16

17
18
19 24. Duque, M. D.; Ma, C.; Torres, E.; Wang, J.; Naesens, L.; Juárez-Jiménez, J.;
20
21
22 Camps, P.; Luque, F. J.; DeGrado, W. F.; Lamb, R. A.; Pinto, L. H.; Vázquez, S.
23
24
25 Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza
26
27
28
29 A virus. *J. Med. Chem.* **2011**, *54*, 2646-2657.
30
31

32
33
34 25. Jones, P. D.; Wolf, N. M.; Morisseau, C.; Whetstone, P.; Hock, B.; Hammock, B.
35
36
37 D. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition
38
39
40 studies. *Anal. Biochem.* **2005**, *343*, 66-75.
41
42
43

44
45 26. Hammock, B. D.; Hwang, S. H.; Weckler, A. T.; Morisseau, C. Sorafenib
46
47
48 derivatives as soluble epoxide hydrolase inhibitors. WO 2012/112570 A1, Aug 23,
49
50
51
52 2012.
53
54
55
56
57

60

- 1
2
3
4 27. Gless, R. D. Processes for the preparation of piperidiny-substituted urea
5
6
7 compounds. US 2008/0207908 A1, Aug 28, 2008.
8
9
10
11 28. Rose, T. E.; Morisseau, C.; Liu, J.-Y.; Inceoglu, B.; Jones, P. D.; Sanborn, J.
12
13
14 R.; Hammock, B. D. 1-Aryl-3(1-acylpiperidin-4-yl)urea inhibitors of human and
15
16
17 murine soluble epoxide hydrolase: structure – activity relationships,
18
19
20
21 pharmacokinetics, and reduction of inflammatory pain. *J. Med. Chem.* **2010**, *53*,
22
23
24 7067-7075.
25
26
27
28
29 29. Lee, K. S. S.; Liu, J.-Y.; Wagner, K. M.; Pakhomova, S.; Dong, H.; Morisseau,
30
31
32 C.; Fu, S. H.; Yang, J.; Wang, P.; Ulu, A.; Mate, C. A.; Nguyen, L. V.; Hwang, S.
33
34
35
36 H.; Edin, M. L.; Mara, A. A.; Wulff, H.; Newcomer, M. E.; Zeldin, D. C.; Hammock,
37
38
39 B. D. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target
40
41
42 residence time and in vivo efficacy. *J. Med. Chem.* **2014**, *57*, 7016-7030.
43
44
45
46
47 30. North, E. J.; Scherman, M. S.; Bruhn, D. F.; Scarborough, J. S.; Maddox, M. M.;
48
49
50
51 Jones, V.; Grzegorzewicz, A.; Yang, L.; Hess, T.; Morisseau, C.; Jackson, M.; McNeil,
52
53
54
55 M. R.; Lee, R. E. Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-
56
57
58
59
60

1
2
3 heteroaryl ureas with improved in vitro pharmacokinetic properties. *Bioorg. Med.*

4
5
6
7 *Chem.* **2013**, *21*, 2587-2599.

8
9
10
11 31. Thalji, R. K.; McAtee, J. J.; Belyanskaya, S.; Brandt, M.; Brown, G. D.; Costell,

12
13
14 M. H.; Ding, Y.; Dodson, J. W.; Eisennagel, S. H.; Fries, R. E.; Gross, J. W.; Harpel,

15
16
17 M. R.; Holt, D. A.; Israel, D. I.; Jolivette, L. J.; Krosky, D.; Li, H.; Lu, Q.; Mandichak,

18
19
20
21 T.; Roethke, T.; Schnackenberg, C. G.; Schwartz, B.; Shewchuk, L. M.; Xie, W.;

22
23
24
25 Behm, D. J.; Douglas, S. A.; Shaw, A. L.; Marino Jr. J. P. Discovery of 1-(1,3,5-

26
27
28 triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.

29
30
31
32 *Bioorg. Med. Chem. Lett.* **2013**, *23*, 3584-3588.

33
34
35
36 32. Lazaar, A. L.; Yang, L.; Boardley, R. L.; Goyal, N. S.; Robertson, J.; Baldwin, S.

37
38
39 J.; Newby, D. E.; Wilkinson, I. B.; Tal-Singer, R.; Mayer, R. J.; Cheriyan, J.

40
41
42
43 Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294,

44
45
46
47 a novel soluble epoxide hydrolase inhibitor. *Br. J. Clin. Pharmacol.* **2016**, *81*, 971-

48
49
50
51 979.

52
53
54
55 33. Bettaieb, A.; Chahed, S.; Tabet, G.; Yang, J.; Morisseau, C.; Griffey, S.;

1
2
3 Hammock, B. D.; Haj, F. G. Effects of soluble epoxide hydrolase deficiency on acute
4
5
6
7 pancreatitis in mice. *PLoS One* **2014**, *9*, e113019.

8
9
10
11 34. Bettaieb, A.; Chahed, S.; Bachaalany, S.; Griffey, S.; Hammock, B. D.; Haj, F.
12
13
14 G. Soluble epoxide hydrolase pharmacological inhibition ameliorates experimental
15
16
17
18 acute pancreatitis in mice. *Mol. Pharmacol.* **2015**, *88*, 281-290.

19
20
21
22 35. Griñán-Ferré, C.; Codony, S.; Pujol, E.; Yang, J.; Leiva, R.; Escolano, C.;
23
24
25
26 Puigoriol-Illamola, D.; Companys-Aleman, J.; Corpas, R.; Sanfeliu, C.; Loza, M. I.;
27
28
29 Brea, J.; Morisseau, C.; Hammock, B. D.; Vázquez, S.; Pallàs, M.; Galdeano, C.
30
31
32
33 Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for
34
35
36
37 Alzheimer's disease. *Neurotherapeutics*, **2020**, [https://doi.org/10.1007/s13311-020-](https://doi.org/10.1007/s13311-020-00854-1)
38
39
40 00854-1.

41
42
43
44 36. Xie, L.; Ochterski, J. W.; Gao, Y.; Han, B.; Caldwell, T. M.; Xu, Y.; Peterson, J.
45
46
47
48 M.; Ge, P.; Ohliger, R. Dipiperazinyl ketones and related analogs. WO
49
50
51 2007/0106496 A2, Feb 8, 2007.

1
2
3 37. Serrano-Hervás, E.; Casadevall, G.; Garcia-Borràs, M.; Feixas, F.; Osuna, S.

4
5
6
7 Epoxide hydrolase conformational heterogeneity for the resolution of bulky
8
9
10 pharmacologically relevant epoxide substrates. *Chem. Eur. J.* **2018**, *24*, 12254-
11
12
13 12258.

14
15
16
17
18 38. Öster, L.; Tapani, S.; Xue, Y.; Käck, H. Successful generation of structural
19
20
21 information for fragment-based drug discovery. *Drug Discovery Today* **2015**, *20*,
22
23
24 1104-1111.

25
26
27
28
29 39. Durrant, J. D.; Votapka, L.; Sorensen, J.; Amaro, R. E. POVME 2.0: An enhanced
30
31
32 tool for determining pocket shape and volume characteristics. *J. Chem. Theory*
33
34
35 *Comput.* **2014**, *10*, 5047-5056.

36
37
38
39
40 40. Codony, S.; Valverde, E.; Leiva, R.; Brea, J.; Loza, M. I.; Morisseau, C.;
41
42
43 Hammock, B. D.; Vázquez, S. Exploring the size of the lipophilic unit of the soluble
44
45
46 epoxide hydrolase inhibitors. *Bioorg. Med. Chem.* **2019**, *27*, 115078.

47
48
49
50
51 41. Contreras-García, J.; Johnson, E. R.; Keinan, S.; Chaudret, R.; Piquemal, J.-P.;
52
53
54 Beratan, D. N.; Yang, W. NCIPLLOT: a program for plotting noncovalent interaction
55
56
57

1
2
3 regions. *J. Chem. Theory Comput.* **2011**, *7*, 625-632.
4
5

6
7
8 42. Guan, D.; Matthews, S. LogP prediction performance with the SMD solvation
9
10 model and the M06 density functional family for SAMPL6 blind prediction challenge
11
12 molecules. *J. Comput.-Aided Mol. Des.* **2020**, *34*, 511-522.
13
14
15
16

17
18
19 43. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput
20
21 artificial membrane permeability assay for blood-brain barrier. *Eur. J. Med. Chem.*
22
23 **2003**, *38*, 223-232.
24
25
26
27

28
29
30 44. Yadav, D.; Lowenfels, A. B. The epidemiology of pancreatitis and pancreatic
31
32 cancer. *Gastroenterology* **2013**, *144*, 1252-1261.
33
34
35
36

37
38 45. Forsmark, C. E.; Vege, S. S.; Wilcox, C. M. Acute pancreatitis. *N. Engl. J. Med.*
39
40
41 **2016**, *375*, 1972-1981.
42
43
44

45
46 46. Krishna, S. G.; Kamboj, A. K.; Hart, P. A.; Hinton, A. ; Conwell, D. L. The
47
48 changing epidemiology of acute pancreatitis hospitalizations: a decade of trends and
49
50 the impact of chronic pancreatitis. *Pancreas* **2017**, *46*, 482-488.
51
52
53
54
55
56

1
2
3 47. Weber, H.; Hüns, S.; Jonas, L.; Sparmann, G.; Bastian, M.; Schuff-Werner, P.

4
5
6
7 Hydrogen peroxide-induced activation of defense mechanisms against oxidative
8
9
10 stress in rat pancreatic acinar AR42J cells. *Free Radic. Biol. Med.* **2007**, *42*, 830-
11
12
13 841.

14
15
16
17
18 48. González, A.; Santofimia-Castaño, P.; Salido, G. M. (2011). Culture of pancreatic
19
20
21 AR42J cell for use as a model for acinar cell function. *Pancreapedia: Exocrine*
22
23
24 *pancreas Knowledge Base*. [https://www.pancreapedia.org/tools/methods/culture-of-](https://www.pancreapedia.org/tools/methods/culture-of-pancreatic-ar42j-cell-for-use-as-model-for-acinar-cell-function)
25
26
27
28 [pancreatic-ar42j-cell-for-use-as-model-for-acinar-cell-function](https://www.pancreapedia.org/tools/methods/culture-of-pancreatic-ar42j-cell-for-use-as-model-for-acinar-cell-function) (accessed December
29
30
31 23, 2019).

32
33
34
35
36 49. Mareninova, O. A.; Orabi, A. I.; Husain, S. Z. (2015). Experimental acute
37
38
39 pancreatitis: in vitro models. *Pancreapedia: Exocrine pancreas Knowledge Base*.
40
41
42 [https://www.pancreapedia.org/reviews/experimental-acute-pancreatitis-in-vitro-](https://www.pancreapedia.org/reviews/experimental-acute-pancreatitis-in-vitro-models)
43
44
45
46 [models](https://www.pancreapedia.org/reviews/experimental-acute-pancreatitis-in-vitro-models) (accessed December 23, 2019).

47
48
49
50
51 50. Afghani, E.; Pandol, S. J.; Shimosegawa, T.; Sutton, R.; Wu, B. U.; Vege, S. S.;
52
53
54 Gorelick, F.; Hirota, M.; Windsor, J.; Lo, S. K.; Freeman, M. L.; Lerch, M. M.; Tsuji,

1
2
3 Y.; Melmed, G. Y.; Wassef, W.; Mayerle, J. Acute pancreatitis-progress and
4
5
6
7 challenges: a report on an international symposium. *Pancreas* **2015**, *44*, 1195-1210.
8

9
10
11 51. Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R. The many faces of the adamantyl
12
13
14 group in drug design. *Eur. J. Med. Chem.* **2011**, *46*, 1949-1963.
15

16
17
18 52. Wanka, L.; Iqbal, K.; Schreiner, P. R. The lipophilic bullet hits the targets:
19
20
21 medicinal chemistry of adamantane derivatives. *Chem. Rev.* **2013**, *113*, 3516-3604.
22

23
24
25 53. Morisseau, C.; Hammock, B. D. Measurement of soluble epoxide hydrolase
26
27
28 (sEH) activity. *Curr. Protoc. Toxicol.* **2007**, Chapter 4, Unit 4.23.
29

30
31
32 54. Case, D. A.; Ben-Shalom, I. Y.; Brozell, S. R.; Cerutti, D. S.; Cheatham, T. E. I.;

33
34
35 Cruzeiro, V. W. D.; Darden, T. A.; Duke, R. E.; Ghoreishi, D.; Gilson, M. K.; Gohlke,

36
37
38 H.; Goetz, A. W.; Greene, D.; Harris, R.; Homeyer, N.; Izadi, S.; Kovalenko, A.;

39
40
41 Kurtzman, T.; Lee, T. S.; LeGrand, S.; Li, P.; Lin, C.; Liu, J.; Luchko, T.; Luo, R.;

42
43
44 Mermelstein, D. J.; Merz, K. M.; Miao, Y.; Monard, G.; Nguyen, C.; Nguyen, H.;

45
46
47 Omelyan, I.; Onufriev, A.; Pan, F.; Qi, R.; Roe, D. R.; Roitberg, A.; Sagui, C.; Schott-

48
49
50 Verdugo, S.; Shen, J.; Simmerling, C. L.; Smith, J.; Salomon-Ferrer, R.; Swails, J.;

1
2
3 Walker, R. C.; Wang, J.; Wei, H.; Wolf, R. M.; Wu, X.; Xiao, L.; York, D. M.; Kollman,
4
5
6
7 P. A. (2018), AMBER 2018, University of California, San Francisco.Ta
8
9

10
11 55. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development
12
13 and testing of a general amber force field. *J. Comput. Chem.* **2004**, *25*, 1157-1174.
14
15
16

17
18 56. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic
19
20 potential based method using charge restraints for deriving atomic charges: the
21
22 RESP model. *J. Phys. Chem.* **1993**, *97*, 10269-10280.
23
24
25
26

27
28
29 57. Besler, B. H.; Merz Jr., K. M.; Kollman, P. A. Atomic charges derived from
30
31 semiempirical methods. *J. Comput. Chem.* **1990**, *11*, 431-439.
32
33
34
35

36
37 58. Singh, U. C.; Kollman, P. A. An approach to computing electrostatic charges for
38
39 molecules. *J. Comput. Chem.* **1984**, *5*, 129-145.
40
41
42
43

44
45 59. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.;
46
47 Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.;
48
49 Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng,
50
51
52 G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.;
53
54
55
56
57

- 1
2
3
4 Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery
5
6
7 Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K.
8
9
10 N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.;
11
12
13 Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene,
14
15
16 M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.;
17
18
19
20
21 Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.;
22
23
24 Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.;
25
26
27
28 Dannenberg, J. J.; S. Dapprich; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J.
29
30
31 V.; Cioslowski, J.; Fox, D. J. *Gaussian 09*, Gaussian 09, Revision A.02; Gaussian,
32
33
34 Inc.: Pittsburgh, PA, 2009).
- 35
36
37
38
39 60. Sagui, C.; Darden, T. A. Molecular dynamics simulations of biomolecules: long-
40
41
42 range electrostatic effects. *Annu. Rev. Biophys. Biomol. Struct.* **1999**, *28*, 155-179.
43
44
45
46
47 61. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the
48
49
50 cartesian equations of motion of a system with constraints: molecular dynamics of
51
52
53 *n*-alkanes. *J. Comp. Phys.* **1977**, *23*, 327-341.
54
55
56
57
58
59
60

1
2
3 62. Wu, X.; Brooks, B. R. Self-guided Langevin dynamics simulation method. *Chem.*
4
5
6
7 *Phys. Lett.* **2003**, *381*, 512-518.
8
9

10
11 63. Song, L. F.; Lee, T.-S.; Zhu, C.; York, D. M.; Merz Jr., K. M. Using AMBER18 for
12
13
14 relative free energy calculations. *J. Chem. Inf. Model.* **2019**, *59*, 3128-3135.
15
16
17

18 64. Zhao, Y.; Truhlar, D. G. The M06 suite of density functionals for main group
19
20
21 thermochemistry, thermochemical kinetics, noncovalent interactions, excited states,
22
23
24 and transition elements: two new functionals and systematic testing of four M06-
25
26
27 class functionals and 12 other functionals. *Theor. Chem. Acc.* **2008**, *120*, 215-241.
28
29
30

31
32 65. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Universal solvation model based
33
34
35 on solute electron density and on a continuum model of the solvent defined by the
36
37
38 bulk dielectric constant and atomic surface tensions. *J. Phys. Chem. B* **2009**, *113*,
39
40
41 6378-6396.
42
43
44

45
46 66. Weigend, F.; Ahlrichs, R. Balanced basis sets of split valence, triple zeta valence
47
48
49 and quadruple zeta valence quality for H to Rn: design and assessment of accuracy.
50
51
52 *Phys. Chem. Chem. Phys.* **2005**, *7*, 3297-3305.
53
54
55
56
57
58
59
60

1
2
3 67. Pufahl, R. A.; Kasten, T. P.; Hills, R.; Gierse, J. K.; Reitz, B. A.; Weinberg, R. A.;
4
5
6
7 Masferrer, J. L. Development of a fluorescence-based enzyme assay of human 5-
8
9
10 lipoxygenase. *Anal. Biochem.* **2007**, *364*, 204-212.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of Contents graphic

